Propanc Biopharma (PPCB) 10-K 30 Sep 24 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jun. 30, 2024	Sep. 25, 2024	Dec. 29, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--06-30
Entity File Number	000-54878
Entity Registrant Name	PROPANC BIOPHARMA, INC.
Entity Central Index Key	0001517681
Entity Tax Identification Number	33-0662986
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	302
Entity Address, Address Line Two	6 Butler Street
Entity Address, City or Town	Camberwell
Entity Address, Country	AU
Entity Address, Postal Zip Code	3124
City Area Code	61 03
Local Phone Number	9882 0780
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 424,536
Entity Common Stock, Shares Outstanding		688,022,017
Documents Incorporated by Reference [Text Block]	None
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	106
Auditor Name	SALBERG & COMPANY, P.A.
Auditor Location	Boca Raton, Florida

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Jun. 30, 2023
CURRENT ASSETS:
Cash	$ 21,085	$ 10,047
GST tax receivable	2,950	2,867
Prepaid expenses and other current assets	1,406	6,125
TOTAL CURRENT ASSETS	25,441	19,039
Deferred offering costs	27,117
Security deposit - related party	2,008	1,999
Property and equipment, net		302
TOTAL ASSETS	72,365	60,328
CURRENT LIABILITIES:
Accounts payable	1,213,335	966,718
Accrued expenses and other payables	792,190	579,707
Accrued interest	94,612	44,709
Note payable, net of discount	204,694
Convertible notes, net of discounts and including put premiums	399,325	390,539
Embedded conversion option liabilities	133,886	423,209
Employee benefit liability	639,371	587,618
TOTAL CURRENT LIABILITIES	3,792,782	3,158,229
NON-CURRENT LIABILITIES:
TOTAL NON-CURRENT LIABILITIES	58,642	19,278
TOTAL LIABILITIES	3,851,424	3,177,507
Commitments and Contingencies (See Note 9)
STOCKHOLDERS’ DEFICIT:
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 478,802,488 and 6,031,250 shares issued and outstanding as of June 30, 2024 and 2023, respectively	478,802	6,031
Common stock issuable (0 and 1,621,653 shares as of June 30, 2024 and 2023, respectively)		1,621
Additional paid-in capital	61,217,255	60,311,502
Accumulated other comprehensive income	1,269,581	1,294,876
Accumulated deficit	(66,698,220)	(64,684,732)
Treasury stock ($0.001 share)	(46,477)	(46,477)
TOTAL STOCKHOLDERS’ DEFICIT	(3,779,059)	(3,117,179)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	72,365	60,328
Series B Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock, value
Related Party [Member]
CURRENT ASSETS:
Operating lease right-of-use assets, net - related party	17,799	38,988
CURRENT LIABILITIES:
Loan from former director - related party	71,629
Operating lease liability - related party, current portion	19,362	21,505
NON-CURRENT LIABILITIES:
Loan payable - long-term - related party, net of discount	58,642
Operating lease liability - long-term portion - related party		19,278
Nonrelated Party [Member]
CURRENT LIABILITIES:
Loan from former director - related party	145,091	65,280
Former Director [Member]
CURRENT LIABILITIES:
Loan from former director - related party	49,528	49,314
Due to former director - related party	$ 29,759	$ 29,630

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2024	Jun. 30, 2023
Preferred stock, shares authorized	1,500,005	1,500,005
Preferred stock, par value	$ 0.01	$ 0.01
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	10,000,000,000	10,000,000,000
Common stock, shares issued	478,802,488	6,031,250
Common stock, shares outstanding	478,802,488	6,031,250
Common stock, shares issuable	0	1,621,653
Treasury stock price per share	$ 0.001	$ 0.001
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5	5
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
REVENUE
Revenue
OPERATING EXPENSES
Administration expenses	1,253,797	1,499,885
Occupancy expenses - related party	34,150	28,841
Research and development	248,102	247,919
TOTAL OPERATING EXPENSES	1,536,049	1,776,645
LOSS FROM OPERATIONS	(1,536,049)	(1,776,645)
OTHER INCOME (EXPENSE)
Interest expense	(665,841)	(532,821)
Interest income	60	36
Derivative expense	(141,012)
Change in fair value of derivative liabilities	316,537	(530,330)
Gain from settlement of accounts payable		17,499
Gain on extinguishment of debt, net	54,565	25,969
Foreign currency transaction gain	22,080	5,885
TOTAL OTHER EXPENSE, NET	(413,611)	(1,013,762)
LOSS BEFORE TAXES	(1,949,660)	(2,790,407)
Tax benefit	129,132	129,841
NET LOSS	(1,820,528)	(2,660,566)
Deemed Dividend	(192,960)	(466,273)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (2,013,488)	$ (3,126,839)
BASIC NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS	$ (0.02)	$ (1.80)
DILUTED NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS	$ (0.02)	$ (1.80)
BASIC WEIGHTED AVERAGE SHARES OUTSTANDING	85,045,339	1,738,802
DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING	85,045,339	1,738,802
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized foreign currency translation gain (loss)	$ (25,295)	$ 60,327
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	(25,295)	60,327
TOTAL COMPREHENSIVE LOSS	$ (2,038,783)	$ (3,066,512)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock, Common [Member]	Total
Balance at Jun. 30, 2022	$ 5,000		$ 220	$ 20	$ 57,364,690	$ (23,758)	$ (61,557,893)	$ 1,234,549	$ (46,477)	$ (3,023,649)
Balance, shares at Jun. 30, 2022	500,000	1	220,351	19,598
Issuance of common stock for cash			$ 14		24,697	23,758				48,469
Issuance of common stock for cash, shares			14,337
Retirement of Series A Preferred Stock	$ (5,000)				5,000
Retirement of Series A Preferred Stock, shares	(500,000)
Issuance of common stock for conversion of convertible debt and accrued interest			$ 5,061	$ 807	1,381,855					1,387,723
Issuance of common stock for conversion of convertible debt and accrued interest, shares			5,061,180	807,230
Issuance of common stock for services			$ 79	$ 608	138,260					138,947
Issuance of common stock for services, shares			79,412	608,423
Issuance of common stock for exercise of Series B warrants					475,000					475,000
Issuance of common stock for exercise of Series B warrants, shares			12
Issuance of common stock for alternate cashless exercise of warrants			$ 560	$ 206	(766)
Issuance of common stock for alternate cashless exercise of warrants, shares			559,999	206,000
Issuance of common stock in connection with a note payable			$ 75		37,425					37,500
Issuance of common stock in connection with a note payable, shares			75,000
Issuance of common stock for issuable shares			$ 20	$ (20)
Issuance of common stock for issuable shares, shares			19,598	(19,598)
Reclassification of put premium upon debt conversion					411,111					411,111
Warrant grant for settlement of accounts payable					5,551					5,551
Stock based compensation in connection with stock warrant grant					2,408					2,408
Foreign currency translation loss								60,327		60,327
Deemed dividend upon alternate cashless exercise of warrants					466,273		(466,273)
Fractional shares due to reverse split			$ 2		(2)
Fractional shares due to reverse split, shares			1,361
Net loss							(2,660,566)			(2,660,566)
Balance at Jun. 30, 2023			$ 6,031	$ 1,621	60,311,502		(64,684,732)	1,294,876	(46,477)	(3,117,179)
Balance, shares at Jun. 30, 2023		1	6,031,250	1,621,653
Issuance of common stock for cash			$ 18,914		4,143					23,057
Issuance of common stock for cash, shares			18,913,648
Issuance of common stock for conversion of convertible debt and accrued interest			$ 445,964		327,584					773,548
Issuance of common stock for conversion of convertible debt and accrued interest, shares			445,963,937
Issuance of common stock for alternate cashless exercise of warrants			$ 6,272		(6,272)
Issuance of common stock for alternate cashless exercise of warrants, shares			6,272,000
Issuance of common stock for issuable shares			$ 1,621	$ (1,621)
Issuance of common stock for issuable shares, shares			1,621,653	(1,621,653)
Reclassification of put premium upon debt conversion					246,254					246,254
Foreign currency translation loss								(25,295)		(25,295)
Deemed dividend upon alternate cashless exercise of warrants					192,960		(192,960)
Net loss							(1,820,528)			(1,820,528)
Relative fair value of warrant granted in connection with a loan payable - related party					141,084					141,084
Balance at Jun. 30, 2024			$ 478,802		$ 61,217,255		$ (66,698,220)	$ 1,269,581	$ (46,477)	$ (3,779,059)
Balance, shares at Jun. 30, 2024		1	478,802,488

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,820,528)	$ (2,660,566)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Issuance and amortization of common stock for services		138,948
Stock option, stock warrants and restricted stock expense		2,408
Foreign currency transaction gain	(22,080)	(5,885)
Depreciation expense	297	1,665
Allowance on refundable advance deposit	120,958
Amortization of debt discounts	294,005	202,952
Amortization of right-of-use assets	21,359	21,266
Change in fair value of derivative liabilities	(316,537)	530,330
Derivative expense	141,012
Gain on extinguishment of debt, net	(54,565)	(25,969)
Gain from settlement of accounts payable		(17,499)
Non-cash interest expense	3,832	1,838
Accretion of put premium	279,711	232,674
Changes in Assets and Liabilities:
GST receivable	(71)	(610)
Prepaid expenses and other assets	4,746	2,182
Refundable advance deposit	(120,958)
Deferred offering costs	(25,000)
Accounts payable	242,408	80,975
Employee benefit liability	49,196	186,912
Accrued expenses and other payables	209,962	130,511
Accrued interest	78,733	92,474
Operating lease liability	(21,598)	(19,857)
NET CASH USED IN OPERATING ACTIVITIES	(935,118)	(1,105,251)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory notes, net of original issue discounts and issue costs	567,050	590,250
Repayment of convertible note	(142,909)
Proceeds from the sale of common stock	23,057	24,711
Proceeds from note payable	190,000
Proceeds from loans payable	79,811
Proceeds from loans payable - related party	224,885
Collection of subscription receivable		23,758
Proceeds from the exercise of warrants		475,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	941,894	1,113,719
Effect of exchange rate changes on cash	4,262	(2,488)
NET INCREASE IN CASH	11,038	5,980
CASH AT BEGINNING OF YEAR	10,047	4,067
CASH AT END OF YEAR	21,085	10,047
Supplemental Disclosure of Cash Flow Information
Interest	9,491	2,883
Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Reduction of put premium related to conversions of convertible notes	246,254	411,111
Conversion of convertible notes and accrued interest to common stock	560,483	1,016,285
Debt discounts related to derivative liability	150,000	93,668
Relative fair value of warrant granted in connection with a loan payable - related party	141,084
Warrant grant for settlement of accounts payable		37,500
Warrants issued for accrued services		5,551
Deemed dividend upon alternate cashless exercise of warrants	$ 192,960	$ 466,273

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) is based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2024, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 84 granted, allowed, or accepted patents and 6 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand (1:1,000) The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development. Principles of Consolidation The consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through June 30, 2024 and remains inactive. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives of long-lived assets, valuation of the collectability of a refundable advance deposit, present value of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly-owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency, which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency translations are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per Accounting Standards Codification (“ASC”) 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). As of June 30, 2024 and 2023, the Company recognized a cumulative exchange gain of approximately $ 90,000 648,000 As of June 30, 2024 and 2023, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES June 30, 2024 June 30, 2023 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6693 0.6664 Average exchange rate for the period USD : AUD exchange rate 0.6557 0.6732 Change in Accumulated Other Comprehensive Income (Loss) by component during the years ended June 30, 2024 and 2023 were as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Currency Items: Beginning balance, June 30, 2022 $ 1,234,549 Foreign currency translation gain 60,327 Balance, June 30, 2023 1,294,876 Foreign currency translation loss (25,295 ) Ending balance, June 30, 2024 $ 1,269,581 Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 12 - Derivative Financial Instruments and Fair Value Measurements. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts, as applicable, are reflected as a current liability on the balance sheets. There were no Refundable Advance Deposit In August 2023, the Company paid a refundable advance deposit of $ 120,958 120,958 Deferred Offering Costs The Company complies with the requirements of ASC 340, Other Assets and Deferred Costs, with regards to offering costs. Prior to the completion of an offering, offering costs are capitalized and consist principally of professional, underwriting and other expenses incurred through the balance sheet date that are directly related to the Company’s proposed public offering. The deferred offering costs are charged to additional paid-in capital or as a discount to debt, as applicable, upon the completion of an offering or to expense if the offering is not completed. As of June 30, 2024 and 2023 the Company had recorded $ 27,117 0 Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Machinery and equipment - 5 Furniture - 7 Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through June 30, 2024 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency. Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 Employee Benefit/Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months. Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of June 30, 2024 and 2023, the Company was owed $ 2,950 2,867 Derivative Instruments ASC Topic 815, Derivatives and Hedging Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of the Company’s common stock, par value $ 0.001 Distinguishing Liabilities from Equity Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 248,102 247,919 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as a tax benefit, in operations, upon receipt. During each of the fiscal years ended June 30, 2024 and 2023, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $ 129,132 129,841 Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption. Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. Legal Expenses All legal costs for litigation are charged to expense as incurred. Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the convertible notes has agreed to a 4.99 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS June 30, 2024 June 30, 2023 Stock Options 0.06 0.06 Warrants with no designations 15,003,396 90 Series A Warrants as if converted at alternate cashless exercise prices 1,990,353,990 1,996,625,990 Series B Warrants 16 16 Series C Warrants as if converted at alternate cashless exercise prices * 9,175,999,954 9,473,999,953 Unvested restricted stock units 0.06 0.06 Convertible Debt 393,727,811 5,991,195 Total 11,575,085,167.12 11,476,617,244.12 * Only convertible ratably upon exercise of Series B Warrants Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term with the exception of those disclosed below. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The Company is currently assessing the impact the new guidance will have on its consolidated financial statements.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the fiscal year ended June 30, 2024, the Company had no revenues, had a net loss of $ 1,820,528 935,118 3,767,341 3,779,059 66,698,220 The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute its business plan. However, there can be no assurances that any or all of these endeavors will be successful. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 – PROPERTY AND EQUIPMENT Property and equipment consist of the following as of June 30: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2024 2023 Office equipment at cost $ 25,543 $ 25,432 Less: Accumulated depreciation (25,543 ) (25,130 ) Total property, plant, and equipment $ - $ 302 Depreciation expense for the years ended June 30, 2024 and 2023 was $ 297 1,665

DUE TO FORMER DIRECTOR - RELATE

DUE TO FORMER DIRECTOR - RELATED PARTY	12 Months Ended
	Jun. 30, 2024
Due To Former Director - Related Party
DUE TO FORMER DIRECTOR - RELATED PARTY	NOTE 4 – DUE TO FORMER DIRECTOR - RELATED PARTY Due to former director – related party represents unsecured advances made primarily by a former director for operating expenses on behalf of the Company, such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amounts owed to the former director at June 30, 2024 and 2023 were $ 29,759 29,630

LOANS

LOANS	12 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
LOANS	NOTE 5 – LOANS Loan from Former Director - Related Party Loan from the Company’s former director at June 30, 2024 and 2023 was $ 49,528 49,314 Loans payable - Related Party Between November 2023 and May 2024, an institutional investor affiliated with one of our directors, Josef Zelinger, loaned the Company an aggregate of $ 71,629 71,629 0 Loan payable -long-term- Related Party On July 5, 2023, the Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement, pursuant to which such investor loaned the Company an aggregate of $ 230,000 153,256 three July 5, 2026 10 15,000,000 0.01 15,000,000 141,084 0.119 0.01 zero 3.00 4.59 268 A portion of the proceeds of such loan were used to repay an outstanding balance of approximately $ 143,000 Accrued interest from this loan amounted to $ 15,158 46,470 153,256 94,614 58,642 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 Loans Payable Crown Bridge Securities Purchase Agreement Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge Partners, LLC (“Crown Bridge”), pursuant to which Crown Bridge purchased a convertible promissory note from the Company (the “Crown Bridge Note”), which had a remaining principal balance of $ 65,280 October 3, 2020 15 65,280 43,520 45,541 35,722 Loans Payable - others In June 2024, the Company entered into loan agreements with two investors who loaned the Company an aggregate of $ 120,000 79,811 June 2025 12 79,811 665 The aggregate principal outstanding on the above loans was $ 145,091 65,280 Loan in default The Crown Bridge Note is currently past due and in default, consisting of $ 65,280 45,541 15

NOTE PAYABLE AND CONVERTIBLE NO

NOTE PAYABLE AND CONVERTIBLE NOTES	12 Months Ended
	Jun. 30, 2024
Note Payable And Convertible Notes
NOTE PAYABLE AND CONVERTIBLE NOTES	NOTE 6 – NOTE PAYABLE AND CONVERTIBLE NOTES Promissory Note On August 15, 2023, the Company issued to an institutional investor (the “August 2023 Lender”) a 10 120,000 132,000 November 15, 2023 10 18 The Company had the right to prepay the principal and accrued but unpaid interest due under the Promissory Note, together with any other amounts that the Company may owe the August 2023 Lender under the terms of the Promissory Note, on or before September 14, 2023 at a 110% premium of the face amount plus accrued and unpaid interest and any other amounts owed to the August 2023 Lender, which increases to (i) 120% if prepaid after such date, but on or before October 14, 2023, and (ii) 130% if prepaid after October 14, 2023 (including on the maturity date), unless the Company and the Lender agree to otherwise effect repayment 130 Accrued interest from this note amounted to $ 15,536 12,000 132,000 0 132,000 1800 Diagonal Lending Promissory Notes On May 24, 2024, the Company entered into a 15 49,200 8,200 6,000 35,000 22 28,290 7,072.50 56,580 7,072.50 On June 10, 2024, the Company entered into a 15 49,200 8,200 6,000 35,000 22 28,290 7,072.50 56,580 7,072.50 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 The Company has right to accelerate payments or prepay in full at any time with no prepayment penalty. At any time following an event of default, the noteholder shall have the right, to convert all or any part of the outstanding and unpaid amount of these notes into shares of common stock. The conversion price of the above notes shall mean 65 35 4.99 150 The total balance of these 1800 Diagonal Lending promissory notes amounted to $ 98,400 1,193 The total balance of the above three promissory notes, net of unamortized discount of $ 25,706 204,694 Convertible Notes The Company’s convertible notes outstanding at June 30, 2024 and 2023 were as follows: SCHEDULE OF CONVERTIBLE NOTES June 30, 2024 June 30, 2023 Convertible notes and debenture $ 313,550 $ 338,362 Unamortized discounts (38,854 ) (38,994 ) Premium, net 124,629 91,171 Convertible notes, net $ 399,325 $ 390,539 Crown Bridge Securities Purchase Agreements Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge, pursuant to which Crown Bridge purchased the Crown Bridge Note from the Company in the aggregate principal amount of $ 108,000 3,000 5,000 100,000 October 3, 2020 15 Additionally, Crown Bridge had the option to convert all or any amount of the Crown Bridge Note at any time after issuance until the later of such note’s maturity date or the date on which the default amount was paid if an event of default occurs, which would be between 110 150 The conversion price of the Crown Bridge Note was equal to 60% (representing a 40% discount) of the lowest closing bid price of the common stock for the ten trading days immediately prior to the delivery of a notice of conversion under such note, including the day upon which such notice was received subject to 4.99 9.99 72,000 The Crown Bridge Note contained certain events of default, upon which principal and accrued interest would become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal accrued at a default interest rate of 15 The total principal amount outstanding under the Crown Bridge Note was $ 65,280 7,232 42,720 28,480 There were 15 st 9,600 6,400 16,000 The total principal amount outstanding under the Crown Bridge Note was $ 65,280 25,930 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 In August 2022, the SEC filed a complaint against Crown Bridge due to its violation of Section 15(a)(1) of the Exchange Act. Crown Bridge agreed to surrender all conversion rights in its currently held convertible notes, including the Crown Bridge Note. Consequently, during fiscal year 2023, the Company reclassified the remaining principal balance of $ 65,280 43,520 0 1800 Diagonal Lending (formerly known as Sixth Street Lending) Securities Purchase Agreements June 30, 2022 Securities Purchase Agreement On June 30, 2022, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC (“1800 Diagonal”), which closed on July 11, 2022, pursuant to which 1800 Diagonal purchased a convertible promissory note (the “July 11, 2022 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 105,000 3,750 June 30, 2023 8 June 29, 2023 Securities Purchase Agreement On June 29, 2023, the Company entered into a securities purchase agreement with 1800 Diagonal, which closed on July 6, 2023, pursuant to which 1800 Diagonal purchased a convertible promissory note (the “July 6, 2023 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 65,000 5,000 June 29, 2024 July 19, 2023 Securities Purchase Agreement On July 19, 2023, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC pursuant to which 1800 Diagonal purchased a convertible promissory note (the “July 19, 2023 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 45,000 5,000 July 19, 2024 August 16, 2023 Securities Purchase Agreement On August 16, 2023, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC pursuant to which 1800 Diagonal purchased a convertible promissory note (the “August 16, 2023 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 55,000 5,000 August 16, 2024 October 20, 2023 Securities Purchase Agreement On October 20, 2023, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC pursuant to which 1800 Diagonal purchased a convertible promissory note (the “October 20, 2023 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 40,000 5,000 October 20, 2024 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 November 29, 2023 Securities Purchase Agreement On November 29, 2023, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC pursuant to which 1800 Diagonal purchased a convertible promissory note (the “November 29, 2023 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 45,000 5,000 September 15, 2024 The following terms shall apply to all the above 1800 Diagonal notes: The 1800 Diagonal Notes bore interest at a rate of 8 During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above note, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110 129 The conversion price for the above notes was equal to a 35 9.99 134,615 The above notes contained certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22 Failure to deliver shares of common stock upon conversion of the above 1800 Diagonal notes within three business days of notice of conversion will result in the Company paying a penalty of $ 1,000 Upon certain events of default, the above 1800 Diagonal notes will become immediately due and payable and the Company must pay 1800 Diagonal 150 The total principal amount outstanding under the above 1800 Diagonal financing agreements was $ 0 250,000 9,863 134,615 ONE44 Capital Securities Purchase Agreements August 15, 2022 Securities Purchase Agreement On August 15, 2022, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “August 15, 2022 ONE44 Note”) from the Company in the aggregate principal amount of $ 110,000 10,000 5,500 August 15, 2022 10 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 February 14, 2023 Securities Purchase Agreement On February 14, 2023, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “February 14, 2023 ONE44 Note”) from the Company in the aggregate principal amount of $ 111,111 11,111 5,500 10 December 8, 2023 Securities Purchase Agreement On December 8, 2023, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “December 8, 2023 ONE44 Note”) from the Company in the aggregate principal amount of $ 150,000 15,000 7,500 10 The following terms shall apply to all of the above ONE44 note: During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to ONE44, together with any other amounts that the Company may owe ONE44 under the terms of the note, at a premium ranging from 120 135 The conversion price for the above ONE44 notes ranges from 60 65 35 40 4.99 133,305 100,000 The above ONE44 notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24 250 th 500 th 20 The total principal amount outstanding under the above ONE44 notes was $ 118,111 4,726 338,700 24,255 182,376 The total principal amount outstanding under the above ONE44 financing agreements was $ 119,300 6,726 148,811 9,909 98,311 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 GS Capital Partners Securities Purchase Agreements August 12, 2022 Securities Purchase Agreement On August 12, 2022, the Company entered into a securities purchase agreement (the “GS Capital Purchase Agreement”) with GS Capital Partners, LLC (“GS Capital”), pursuant to which GS Capital purchased a convertible redeemable note (the “GS Capital Note”) from the Company in the aggregate principal amount of $ 93,000 5,000 3,000 85,000 The maturity date of the GS Capital Note was April 12, 2023 8 The GS Capital Note was exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital by surrendering the same. GS Capital was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2.80 per share (the “Fixed Price”). However, in the event the common stock trades below $2 per share for more than five consecutive trading days, then the Fixed Price becomes $1.30 per share 65 4.99 September 21, 2022 Securities Purchase Agreement On September 21, 2022, the Company entered into a securities purchase agreement with GS Capital, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 71,500 4,000 2,500 65,000 The maturity date of such note was March 21, 2023 8 Such note was exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2 (the “September Fixed Price”). However, in the event the common stock trades below $1.40 per share for more than five consecutive trading days, then the September Fixed Price becomes $0.90 per share 65 4.99 August 23, 2023 Securities Purchase Agreement On August 23, 2023, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 77,500 5,000 2,500 The maturity date of the GS Capital Note was February 23, 2024 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.04 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.02 per share in the event that the market price of the Common Stock trades below $0.03 per share for five consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default October 12, 2023 Securities Purchase Agreement On October 12, 2023, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 61,000 3,500 2,500 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 The maturity date of the GS Capital Note was April 12, 2024 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.015 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.01 per share in the event that the market price of the Common Stock trades below $0.0075 per share for ten consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default April 12, 2024 Securities Purchase Agreement On April 12, 2024, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 27,500 2,500 The maturity date of the GS Capital Note is October 12, 2024 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0017 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.001 per share in the event that the market price of the Common Stock trades below $0.0014 per share for five consecutive trading days The following terms shall apply to all of the above GS Capital notes: Pursuant to the above GS Capital notes, in the event that such conversion price is below the par value of the Common Stock, the Company has agreed to take all steps to reduce such par value or conduct a reverse split of its Common Stock, as applicable. Notwithstanding the foregoing, such conversion price and lookback periods are subject to adjustment in favor of the Investor in the event the Company issues securities to another party with more favorable conversion terms, and such conversions are subject to a 4.99 Additionally, the conversion prices of the above GS Capital notes will be adjusted in favor of the note holder if the Company issues securities with more favorable conversion terms. The effective conversion price of the outstanding GS Capital notes are 60 40 The above GS Capital notes were bifurcated from the embedded conversion option which was recorded as derivative liabilities at fair value. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 During the first 60 to 180 days following the date of the above GS Capital notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to GS Capital, together with any other amounts that the Company may owe GS Capital under the terms of the notes, at a premium ranging from 110 125 Upon the occurrence and during the continuation of certain events of default, interest accrues at a default interest rate of 24 250 th 500 th 20 The total principal outstanding and accrued interest under the above GS Capital notes were $ 75,300 4,263 89,200 2,945 75,300 The total principal outstanding and accrued interest under the above GS Capital notes were $ 110,500 8,364 130,800 8,700 1,254 3,832 83,000 24 110,500 Red Road Holdings Securities Purchase Agreement On October 6, 2022, the Company entered into a securities purchase agreement (the “Red Road Purchase Agreement”) with Red Road Holdings Corporation, a Virginia corporation (“Red Road”), pursuant to which Red Road purchased a convertible promissory note (the “Red Road Note”) from the Company in the aggregate principal amount of $ 53,750 50,000 8 22 3,750 The conversion price for the Red Road Note was equal to the Variable Conversion Price (subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Company relating to the Company’s securities or the securities of any subsidiary of the Company, combinations, recapitalization, reclassifications, extraordinary distributions and similar events), which was defined as 65 35 4.99 28,942 The Red Road Note may be prepaid until 180 days from its issuance date, subject to the following: if prepaid within 60 days of the issuance date, the prepayment premium is 110% of the face amount of such note plus any accrued interest, if prepaid after 60 days but less than 91 days from the issuance date, then the prepayment premium is 115% of the face amount plus any accrued interest of such note., if prepaid after 90 days but less than 121 days from the issuance date, then the prepayment premium is 120% of the face amount plus any accrued interest of such note, if prepaid after 120 days but less than 151 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest of such note, and if prepaid after 150 days but less than 181 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest of such note In the event that the Company failed to deliver to Red Road shares of common stock upon conversion of the Red Road Note within three business days of a notice of conversion by Red Road, the Company would incur a penalty of $ 1,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 The total principal amount outstanding and accrued interest under the above Red Road notes was $ 0 53,750 2,150 28,942 Coventry Enterprises, LLC Securities Purchase Agreement On November 3, 2022, the Company entered into a Securities Purchase Agreement with Coventry Enterprises, LLC (“Coventry”), pursuant to which the Company issued Coventry a promissory note from the Company in the aggregate principal amount of $ 125,000 25,000 100,000 The Coventry Note bears interest at a rate of 10 12,500 19,643 Additionally, in the event that the Company files with the SEC a qualified offering statement on Form 1-A and such note has been outstanding for four months since its issuance, Coventry has the right to convert all or portion of such note, including guaranteed interest, into shares of common stock at the offering price used in connection with such offering. At any time following an event of default under the Coventry Note, it becomes convertible, in whole or in part, into shares of Common Stock at the option of Coventry, at any time and from time to time thereafter (subject to the beneficial ownership limitations set forth therein). The conversion price of the Coventry Note is ninety percent (90%) per share of the lowest per-share VWAP during the twenty (20) trading-day period before the conversion (each, a “Calculated Conversion Price”). In the event that, within 30 calendar days either before or after any conversion, the conversion price of which is based upon a Calculated Conversion Price, the Company consummates (in whole or in part) any financing (whether such financing is equity, equity-equivalent, or debt or any combination thereof) or for any other reason issues any shares of common stock or any common stock equivalents at a price less than the most recent Calculated Conversion Price (the “Alternative Conversion Price”), regardless of when that note or instrument was originated, then, at the option of Coventry, (i) if the conversion has not yet occurred, then the Alternative Conversion Price will be substituted for the Calculated Conversion Price and (ii) if the conversion has occurred, then, within two trading days following Coventry’s written request, the Company is required to issue to Coventry that number of shares of Common Stock equivalent to the difference between the number of shares of Common Stock that had been issued using the Calculated Conversion Price and the number of shares of Common Stock that would have been issued using the Alternative Conversion Price. Accordingly, the Coventry note is treated as stock settled debt under ASC 480 and the Company recorded a total of $ 13,889 Upon the occurrence and during the continuation of certain events of default, interest on the Coventry Note accrues at a default interest rate equal to the lesser of (i) 18% per annum or (ii) the maximum rate permitted by law. Subject to the beneficial ownership limitation in the Coventry Note, if any event of default occurs, then the outstanding principal amount guaranteed interest plus accrued but unpaid default rate interest, liquidated damages and other amounts owing on the Coventry Note through the date of acceleration becomes immediately due and payable at Coventry’s option, in cash or in shares of common stock at the mandatory default amount, which is equal to 120% of all such amounts due on the Coventry Note. If the Company fails to deliver to Coventry such shares, the Company is required to pay in cash an amount equal to the amount that the value of such shares exceeds the principal amount and interest of the attempted conversion. As an additional inducement to Coventry entering into such agreement, the Company issued to Coventry 75,000 37,500 The Company failed to make the first installment payment due in March 2023 which is considered an event of default. The Company recorded a default penalty of $ 25,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 The total principal amount outstanding and accrued interest under the above Coventry note was $ 144,951 5,049 22,749 561 In July 2023, the Company fully paid the remaining principal of $ 142,909 70 142,979 0 2,043 357 13,328 104 LLC Securities Purchase Agreement March 5, 2024 Securities Purchase Agreement Effective March 5, 2024, the Company entered into and closed a securities purchase agreement (the “Purchase Agreement”) with 104 LLC (“104”), pursuant to which 104 agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $ 50,000 46,875 3,125 7,500 March 1, 2025 8 16 June 20, 2024 Securities Purchase Agreement Effective June 20, 2024, Company entered into and closed a securities purchase agreement with 104 LLC, pursuant to which 104 agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $ 33,750 30,375 3,375 5,200 June 20, 2025 8 16 The principal and interest on the notes are convertible into shares of common stock of the Company at the option of 104 at any time following the issuance date of the notes (the “Conversion Shares”) at a price per share equal to 65 35 4.99 45,096 During the first 60 days following the date of the notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the notes, at a one hundred ten percent (110%) premium of the face amount plus accrued and unpaid interest, which increases to (i) one hundred fifteen percent (115%) if prepaid after 60 days, but less than 91 days from the issuance date, (ii) one hundred twenty percent (120%) if prepaid after 90 days, but less than 121 days from the issuance date, (iii) one hundred twenty five percent (125%) if prepaid after 120 days, but less than 181 days from the issuance date. After this initial 180-day period, the Company does not have a right to prepay the notes PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 The 104 notes contain certain events of default, including failure to pay principal and interest when due, failure to timely issue the conversion shares, failure to maintain the listing of the common stock on at least one of the OTC markets (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, failure to comply with its reporting requirements with the U.S. Securities and Exchange Commission, a breach of certain covenants in the purchase agreement, default by the Company under any other note issued to the Investor, as well as certain customary events of default set forth in the notes, including, among others, breach of covenants, representations or warranties, insolvency, bankruptcy, and liquidation. Upon an event of default, the notes will become immediately due and payable by the Company. The total principal amount outstanding under the above 104 financing agreements was $ 83,750 1,429 Outstanding convertible notes in default Outstanding convertible notes for total principal amount of $ 83,000 maturity dates between February 23, 2024 and April 12, 2024 Amortization of debt discounts The Company recorded $ 232,700 210,278 279,711 232,674 Amortization of all debt discounts for the years ended June 30, 2024 and 2023 was $ 294,005 202,952 The Company reclassified $ 246,254 411,111

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 7 – INCOME TAXES The Company follows ASC 740-10-10, under which an entity recognizes deferred tax assets and liabilities for future tax consequences or for events that were previously recognized in the Company’s financial statements or tax returns. The measurement of deferred tax assets and liabilities is based on enacted tax law provisions. The effects of future changes in tax laws or rates are not anticipated. Through June 30, 2010, the Company operated exclusively in Australia. The Company was wholly subject to Australian income tax laws and regulations, which are administered by the Australian Taxation Office for the years ended June 30, 2010 and all prior years. On November 23, 2010, the Company was incorporated in the state of Delaware. In January 2011, the Company acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis with Propanc PTY LTD becoming a wholly owned subsidiary of the Company. As a result of these transactions, the Company is subject to the income tax laws of both the United States and Australia for the years ended June 30, 2013 through June 30, 2024. The reconciliation of income tax expense computed at the U.S. federal statutory rate of 21% to the income tax provision for the years ended June 30, 2024 and 2023 is as follows: PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 SCHEDULE OF INCOME TAX PROVISION US June 30, 2024 June 30, 2023 Year Ended US June 30, 2024 June 30, 2023 Loss before Income taxes $ (1,874,914 ) $ (2,790,407 ) Taxes under statutory US tax rates $ (393,732 ) $ (585,986 ) Increase (decrease) in valuation allowance 306,682 556,521 Foreign tax rate differential (55,358 ) (60,316 ) Prior period adjustment 76,194 81,599 Other 66,214 8,182 Income tax (expense) benefit $ - $ - The Company reflects a tax benefit on its consolidated statement of operations and comprehensive income (loss) in 2024 and 2023 of $ 129,132 129,841 On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities consist of the following: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES June 30, 2024 June 30, 2023 Year Ended June 30, 2024 June 30, 2023 Deferred tax assets Warrant Derivative Liability $ 513,071 $ 579,544 Accrued Expenses 559,723 478,273 Prepaid Investor Services 551,796 575,021 Non-cash interest 817,536 758,797 Intangibles (Intellectual Property and Patent Cost) 351,144 321,557 Deferred Rent 4,492 4,550 Formation Expense 6,553 6,553 Net Operating Loss carryforward 9,075,029 8,910,874 Gain on extinguishment of debt 97,992 47,393 Stock Based Compensation 84,028 84,028 Total Deferred tax assets $ 12,061,364 $ 11,766,590 Deferred tax liabilities Research and Development $ (170,435 ) $ (202,568 ) Foreign Exchange Loss (OCI) (39,379 ) (39,379 ) Capital Raising Costs (389,258 ) (369,033 ) Total deferred tax liabilities $ (599,072 ) $ (610,980 ) Net deferred tax assets $ 11,462,292 $ 11,155,610 Valuation allowance (11,462,292 ) (11,155,610 ) Net deferred tax assets $ - $ - PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 At June 30, 2024, the Company had U.S. net operating loss carry forwards of $ 10,601,740 10.6 7.2 3.4 25 27,394,654 No The Company applied the “more-likely-than-not” recognition threshold to all tax positions taken or expected to be taken in a tax return, which resulted in no Management has determined that the realization of the net deferred tax asset is not assured and has created a valuation allowance for the entire amount of such benefits. The Company follows ASC 740-10, which provides guidance for the recognition and measurement of certain tax positions in an enterprise’s financial statements. Recognition involves a determination whether it is more likely than not that a tax position will be sustained upon examination with the presumption that the tax position will be examined by the appropriate taxing authority having full knowledge of all relevant information. The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the consolidated statement of operations. As of June 30, 2024, the Company had no no The income tax returns filed for the tax years from inception will be subject to examination by the relevant taxing authorities.

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	12 Months Ended
	Jun. 30, 2024
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 8 – STOCKHOLDERS’ DEFICIT Increase in Authorized Shares of Common Stock and Reverse Stock Split On May 18, 2022, the board of directors of the Company approved and authorized, and the holders of a majority-in-interest of the Company’s voting capital stock approved by written consent for the Company to file a certificate of amendment to its certificate of incorporation, as amended (the “Certificate of Incorporation”), which increased the Company’s authorized capital stock. Such certificate of amendment increased the number of authorized shares of common stock from 1,000,000,000 3,000,000,000 1,500,005 3,001,500,005 On September 21, 2022, the board of directors of the Company approved and authorized, and the holders of a majority-in-interest of the Company’s voting capital stock approved by written consent for the Company to file a certificate of amendment to its Certificate of Incorporation, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of common stock from 3,000,000,000 10,000,000,000 1,500,005 10,001,500,005 On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand (1:1,000) PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 Preferred Stock The total number of shares of preferred stock that the Company is authorized to issue is 1,500,005 0.01 Of the total preferred shares authorized, 500,000 On March 15, 2023, the Company filed a certificate with the Secretary of State of Delaware (the “Certificate of Retirement”), effecting the retirement and cancellation of the Series A Preferred Stock to eliminate such Series A Preferred Stock. No Pursuant to a certificate of designation filed with the Secretary of State of the State of Delaware on June 16, 2015, five shares of preferred stock have been designated as Series B Preferred Stock, par value $ 0.01 One No Common Stock Shares issued under the Equity Lines Dutchess Capital Growth Fund LP On November 30, 2021, the Company entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Dutchess Capital Growth Fund LP, a Delaware limited partnership, (“Dutchess”), providing for an equity financing facility (the “Equity Line”). The Purchase Agreement provides that upon the terms and subject to the conditions in the Purchase Agreement, Dutchess is committed to purchase up to Five Million Dollars ($ 5,000,000 36 Under the terms of the Purchase Agreement, Dutchess will not be obligated to purchase shares of Common Stock unless and until certain conditions are met, including but not limited to a Registration Statement on Form S-1 (the “Registration Statement”) becoming effective which registers Dutchess’ resale of any Common Stock purchased by Dutchess under the Equity Line. From time to time over the 36-month term of the Purchase Agreement, commencing on the trading day immediately following the date on which the Registration Statement becomes effective, the Company, in our sole discretion, may provide Dutchess with a draw down notice (each, a “Draw Down Notice”), to purchase a specified number of shares of Common Stock (each, a “Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Draw Down Notice (each, a “Draw Down Amount”) is to be determined by multiplying the Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of Common Stock equals 92 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 The maximum number of shares of Common Stock requested to be purchased pursuant to any single Draw Down Notice cannot exceed the lesser of (i) 300 250,000 On July 13, 2022, the Company issued 14,337 2 24,711 23,758 On July 20, 2023, the Company entered into a common stock purchase agreement (the “Equity Line Agreement”) with Dutchess Capital Growth Fund LP (the “Investor”) providing for an equity financing facility, pursuant to which Company has the option to request that the Investor commit to purchase up to $ 5,000,000 0.001 24 Pursuant to the Equity Line Agreement, purchases of Shares cannot occur unless and until certain conditions are met, including but not limited to, the SEC declaring the Registration Statement effective, and the maximum number of Shares that may be purchased pursuant to a Drawdown Notice cannot exceed the lesser of (i) 200% of the average daily traded value of the Common Stock during the five (5) business days immediately preceding a Drawdown Notice or (ii) $200,000; provided that in no event may a Drawdown Notice be for less than $5,000, exceed 52,500,000 Shares or cause the Investor’s ownership to exceed 4.99% of the outstanding number of shares of Common Stock immediately prior to the issuance of such Shares. The actual amount of proceeds that the Company will receive in connection with each Drawdown Notice is determined under the Equity Line Agreement by multiplying the number of Shares to be sold by the applicable purchase price per share, which is equal to 85% of the lowest traded price of the Common Stock during the 7 business days immediately following the Clearing Date, less Clearing Costs (as each such term is defined in the Equity Line Agreement) On December 13, 2023, the Company issued 1,390,008 0.006 8,822 8,822 On February 20, 2024, the Company issued 1,755,240 0.0013 2,260 On June 11, 2024, the Company issued 15,768,400 0.0008 11,975 Coventry Enterprises, LLC On November 3, 2022, the Company entered into a Common Stock Purchase Agreement (the “Coventry Purchase Agreement”) with Coventry providing for an equity financing facility (the “Coventry Equity Line”). The Purchase Agreement provides that, upon the terms and subject to the conditions in the Purchase Agreement, Coventry is committed to purchase up to Five Million Dollars ($ 5,000,000 36 Under the terms of the Coventry Purchase Agreement, Coventry will not be obligated to purchase shares of common stock unless and until certain conditions are met, including but not limited to a registration statement on Form S-1 becoming effective which registers Coventry’s resale of any common stock purchased by Coventry under the Coventry Equity Line. From time to time over the 36-month term of the Coventry Purchase Agreement, commencing on the trading day immediately following the date on which such registration statement becomes effective, the Company, in its sole discretion, may provide Coventry with a draw down notice (each, a “Coventry Draw Down Notice”), to purchase a specified number of shares of common stock (each, a “Coventry Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Coventry Draw Down Notice (each, a “Coventry Draw Down Amount”) is to be determined by multiplying the Coventry Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of common stock equals 80% of the lowest volume weighted average price of the Common Stock during the 10 business days immediately preceding the Coventry Drawdown Notice date. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 The maximum number of shares of common stock requested to be purchased pursuant to any single Coventry Draw Down Notice cannot exceed the lesser of (i) 200 250,000 9.99 Shares issued for conversion of convertible debt During the year ended June 30, 2023, the Company issued an aggregate of 5,061,180 807,230 0.17 935,699 80,586 1,838 807,230 Included in the above conversion during the year ended June 30, 2023 were principal aggregate amount of convertible notes of $ 168,200 16,632 1,838 556,272 369,602 352,051 17,551 During the year ended June 30, 2024, the Company issued an aggregate of 445,963,937 0.0013 531,654 28,829 3,832 Included in the above conversion during the year ended June 30, 2024 were aggregate principal amounts of convertible notes of $ 130,800 8,700 3,832 352,565 209,233 263,798 54,565 The Company has 6,973,534,490 Shares issued for services and accrued expenses On October 25, 2022, the Company issued 6,111 0.90 5,500 On November 16, 2022, the Company issued 73,301 0.07 51,311 51,311 On June 30, 2023, the Board approved the issuance of 608,423 608,423 0.135 82,137 82,137 608,423 Shares issued for exercise of warrants During the year ended June 30, 2023, the Company received aggregate gross proceeds of $ 475,000 12 40,000 12 During the year ended June 30, 2023, the Company issued an aggregate of 559,999 206,000 0.97 200,000 0.001 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 During the year ended June 30, 2024, the Company issued an aggregate of 6,272,000 0.0314 200,000 0.001 The Alternate Cashless Exercise provision, for a cashless conversion at the holder’s option, is available should the trading price of the Company’s common stock fall below $ 200,000 70 192,960 466,273 Shares issued in connection with a convertible note On November 3, 2022, the Company entered into a securities purchase agreement with Coventry, pursuant to which Coventry purchased a promissory note from the Company in the aggregate principal amount of $ 125,000 75,000 37,500 Restricted Stock Units Pursuant to employment agreements dated in May 2019, the Company granted an aggregate of 0.078 0.039 0.117 0.117 4,250,000 497,240 248,620 0.06 248,620 Stock Options A summary of the Company’s stock option activity during the years ended June 30, 2024 and 2023 is presented below: SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY Weighted Number of Average Options Price Per Share Outstanding at June 30, 2022 0.059 $ 4,533,000 Issued - - Exercised - - Expired - - Outstanding at June 30, 2023 0.059 $ 4,533,000 Issued - - Exercised - - Expired - - Outstanding at June 30, 2024 0.059 $ 4,533,000 Exercisable at June 30, 2024 0.059 $ 4,533,000 Outstanding and Exercisable: Weighted average remaining contractual term 4.87 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ - On the Effective Date, the Company’s board of directors approved and adopted the Company’s 2019 Equity Incentive Plan (the “2019 Plan”), which reserves a total of 234 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 During the years ended June 30, 2024 and 2023, the Company recognized stock-based compensation of $ 0 0 No Stock Warrants The following table summarizes common stock warrant activity for the years ended June 30, 2024 and 2023: SCHEDULE OF WARRANT ACTIVITY Weighted Number of Average Warrants Price Per Share Outstanding at June 30, 2022 105 $ 200,270 Issued 3,305 10 Exercised (13 ) 52,081 Forfeited (1 ) 2,000,000 Expired - - Outstanding at June 30, 2023 3,396 $ 5,440 Issued 15,000,000 0.01 Exercised - - Forfeited - - Expired - - Outstanding at June 30, 2024 15,003,396 * $ 1.24 Exercisable at June 30, 2024 15,003,378 $ 1.24 Outstanding and Exercisable: Weighted average remaining contractual term 2.01 Aggregate intrinsic value $ - * The total warrants of 15,003,396 SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 10 10 Series B warrants 17 17 Series C warrants 64 46 Common stock warrants with no class designation 15,003,305 15,003,305 Total 15,003,396 15,003,378 In connection with the issuance of shares on April 3, 2020, the Company closed on a transaction related to a Securities Purchase Agreement (the “Securities Purchase Agreement”) entered into on March 30, 2020, whereby an investor purchased from the Company, 7.5 units, each consisting of (i) 1.5 shares of the Company’s common stock, or pre-funded warrants upon Investor’s election due to the 4.99% blocker provision and (ii) 1.5 warrants to purchase one share of Common Stock (“Series A Warrants”, and collectively with the Common Stock the “Units”). 64 64 10 100 Series A Warrants Pursuant to the Securities Purchase Agreement entered into March 20, 2020 as discussed above, the Investor purchased Series A Warrants to purchase up to 11 200,000 3 the Series A Warrants contain a provision for a cashless conversion at the Holder’s option should the trading price of the Common Stock fall below $200,000, per share calculated based on the difference between the exercise price of the Series A Warrant and 70% of the Market Price, as defined therein (the” Alternate Cashless Exercise”). The Alternate Cashless Exercise price is $0.001. See above “Shares issued for exercise of warrants” for discussion of deemed dividend related to alternate cashless exercise PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 Series B Warrants Pursuant to the Securities Purchase Agreement entered into March 20, 2020 as discussed above, the Investor purchased Series B Warrants to purchase up to 64 38 10 4 4 40,000 3 Series C Warrants Pursuant to the Securities Purchase Agreement entered into March 20, 2020 as discussed above, the Investor purchased Series C Warrants to purchase up to 64 3 200,000 Letter Agreement to Extend Termination Dates. On March 8, 2023, the Company agreed with the holder of Series B Warrants (the “Holder”) pursuant to a letter agreement to exercise up to $ 250 1. Effective upon the execution of such letter agreement, the Holder will exercise 4 150,000 4 2. Within 5 business days’ written notice to the Holder from the Company of receipt of approval by the Financial Industry Regulatory Authority, Inc. (“FINRA”) of the Company’s next anticipated reverse stock split, an additional $ 100,000 3 As an inducement to exercise the Existing Warrants, the Company agreed to extend the termination date of the Existing Warrants and the Series A Warrants held by the Holder to March 27, 2025, and to extend the termination date of the Series C Warrants held by the Holder to the third anniversary of the last vesting date of such warrants, effective upon the exercise of the first $ 150,000 In accordance with ASC 815-40-35-17(c), the effect of a modification or an exchange of an equity classified freestanding written call option shall be measured as the difference between the fair value of the modified instrument and the fair value of that instrument immediately before it is modified. The Company recognized the effect of the modifications of the warrants above that is directly attributable to an actual equity offering as an equity issuance cost which amount is not material. The modified warrants are determined to be equity classified, accordingly, the incremental fair value and equity issuance cost were both recognized in additional paid in capital and therefore, there was no effect in equity and such value is de minimis. Warrants Issued to Vendors On August 16, 2022, the Company entered into an agreement with a certain consultant to provide services over a three-month period in exchange for 1,000 10 August 16, 2025 2,408 2.60 10 zero 3.00 3.19 236 2,408 On August 16, 2022, the Company and a third-party investor relations consultant agreed to settle an outstanding payable of $ 23,050 2,305 10 5,551 2.60 10 zero 3.00 3.19 236 17,499 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 Warrants Granted to Lender – Related Party July 5, 2023, the Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement, pursuant to which such investor loaned the Company an aggregate of $ 230,000 153,256 three 15,000,000 0.01 15,000,000 141,084 0.119 0.01 zero 3.00 4.59 268 Exercise of Warrants During the year ended June 30, 2023, the Company received aggregate gross proceeds of $ 475,000 12 40,000 12 During the year ended June 30, 2023, the Company issued an aggregate of 559,999 206,000 0.97 200,000 0.001 During the year ended June 30, 2024, the Company issued an aggregate of 6,272,000 0.0314 200,000 0.001

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES Legal Matters From time to time, the Company may be subject to litigation and claims arising in the ordinary course of business. The Company is not currently a party to any material legal proceedings and the Company is not aware of any pending or threatened legal proceeding against the Company that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition. IRS Liability As part of its requirement for having a foreign operating subsidiary, the Company is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $ 10,000 30,000 Operating Agreements In November 2009, the Company entered into a commercialization agreement with the University of Bath (UK) (the “UK University”), whereby the Company and the UK University co-owned the intellectual property relating to the Company’s pro-enzyme formulations. In June 2012, the Company and the UK University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property, while agreeing to pay royalties of 2 5 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 Collaboration Agreement On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 52,000 59,508 40,000 45,775 2 On October 1, 2020, the Company entered into another two-year collaboration agreement with the University to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 30,000 35,145 5,000 5,000 5,858 10,000 11,715 10,000 11,715 25,837 30,268 2 On July 27, 2022, the Company entered into a two-year research agreement with the University to provide certain research and experiment services to the Company. One of the Company’s Scientific Advisory Board is the lead joint researcher of the University. In exchange for full ownership of the intellectual property, the Company agreed to pay royalties of 1 53,200 53,806 - 18,200 18,407 - 8,000 8,091 - 7,000 7,080 - 10,000 10,114 - 10,000 10,114 The commencement date for the experiments was on September 1, 2022, and the estimated length of time for completion is 24 months. As of June 30, 2024 and 2023, the Company has $ 47,531 18,056 no Consulting Agreements On July 1, 2022, the Company and a consultant agreed to extend the term of a consulting agreement from July 1, 2022 to June 30, 2023 to provide media-related services for a monthly fee of $ 50,000 9.9 9.9 73,301 608,423 0 On May 4, 2024, the Company entered into an Engagement Agreement (the “Agreement”) with EF Hutton LLC (the “Consultant”) which will act as an exclusive lead underwriter, financial advisor, placement agent and investment banker of the Company, whereby the Consultant will assist the Company to a public offering and uplisting of the Company’s equity, debt or equity derivative instruments (“Offering”). The engagement period shall end on the earlier of i) 12 months from the date of this agreement or ii) the final closing if any of the Offering. The Consultant will prepare an Underwriting Agreement (the “Underwriting Agreement”) covering the sale of up to $ 15 (a) Financing Fees: (i) For private equity and equity-linked placements, pay the Consultant a cash fee of eight percent ( 8.0 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 (ii) For debt placements, pay the Consultant a cash fee of six percent ( 6.0 (iii) As additional compensation for EF Hutton’s services, the Company shall issue to the Consultant or its designees at the closing warrants (the “Warrants”) to purchase that number of shares of Common Stock equal to three percent ( 3.0 five years Additionally, the Consultant shall be entitled to a cash fee equal to eight percent ( 8.0 (b) Merger, acquisition or sale of stock or assets (the “M&A Transaction”) Fees: The M&A Transaction fees shall be payable to the Consultant in cash at the closing or closings of the M&A Transaction to which it relates and shall be equal to five percent ( 5.0 The Company will be responsible for and will pay all expenses relating to the Offering as defined in the Agreement. Additionally, the Company will provide an expense advance (the “Advance”) to the Consultant of $ 50,000 25,000 25,000 25,000 Operating Leases – Related Party On May 4, 2022, the Company entered in a three 3,000 2,176 66,201 66,201 8 ROU is summarized below: SCHEDULE OF RIGHT OF USE ASSET June 30, 2024 June 30, 2023 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (48,402 ) (27,213 ) Right-of-use asset, net $ 17,799 $ 38,988 Operating Lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY June 30, 2024 June 30, 2023 Office lease $ 66,201 $ 66,201 Reduction of lease liability (46,839 ) (25,418 ) Less: office lease, current portion (19,362 ) (21,505 ) Long term portion of lease liability $ - $ 19,278 Remaining future minimum lease payments under non-cancelable operating lease at June 30, 2024 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2025 $ 20,079 Imputed interest (717 ) Total operating lease liability $ 19,362 The weighted average remaining lease term for the operating lease is 0.76 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	12 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS AND BALANCES	NOTE 10 – RELATED PARTY TRANSACTIONS AND BALANCES Since its inception, the Company has conducted transactions with its directors and entities related to such directors. These transactions have included the following: As of June 30, 2024 and 2023, the Company owed its former director a total of $ 29,759 29,630 As of June 30, 2024 and 2023, the Company owed its former director a total of $ 49,528 49,314 Effective May 5, 2016, the Company entered into an agreement for the lease of its principal executive offices with North Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our CEO, CFO and a director, and his wife are owners and directors. The lease had a five-year 39,600 28,325 3,600 2,575 198,000 141,629 Such lease expired in May 2021 and was renewed for another one-year term from May 2021 to May 2022. 3,000 2,176 194,129 129,930 158,129 105,377 34,150 28,841 Loans payable - Related Party In November 2023, an institutional investor affiliated with one of our directors, Josef Zelinger, loaned the Company an aggregate of $ 71,629 Loan payable -long-term- Related Party July 5, 2023, the Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement, pursuant to which such investor loaned the Company an aggregate of $ 230,000 153,256 three July 5, 2026 10 15,000,000 0.01 Employment and Services Agreements with Management The Company and Mr. Nathanielsz entered into an employment agreement as of February 25, 2015 (the “Nathanielsz Employment Agreement”) setting forth the terms and conditions of Mr. Nathanielsz’s employment as the Company’s President and Chief Executive Officer. The Nathanielsz Employment Agreement was scheduled to expire on February 25, 2019 25,000 300,000 205,680 9.5 200 300,000 205,680 400,000 274,240 400,000 309,313 600,000 414,900 Mr. Nathanielsz’s wife, Sylvia Nathanielsz, is and has been a non-executive, part-time employee of the Company since October 2015. Effective February 1, 2018, Mrs. Nathanielsz receives an annual salary of $ 120,000 80,904 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 Pursuant to a February 25, 2016 board resolution, James Nathanielsz was paid $ 4,481 3,205 7,689 5,577 17,714 3,344 On August 12, 2021, the Board approved a bonus of $ 177,840 221,890 166,418 422,610 316,957 177,840 5,928,000 140,000 96,810 144,166 99,691 181,324 125,386 73,387 48,905 107,937 71,929 A total of $ 25,000 16,070 150,000 102,195 217,540 145,599 Amended and Restated Employment Agreement On May 14, 2019 (the “Effective Date”), the Company entered into an Amended and Restated Employment Agreement (the “Employment Agreement”) with Mr. Nathanielsz for a term of three years 400,000 309,313 0.04 4,675,000 110 4,250,000 0.04 0.04 10 0.04 0.04 On October 26, 2022, the Company entered into an Amended and Restated Employment Agreement (the “Amended Agreement”) with Mr. Nathanielsz, effective as of July 1, 2022, (the “2022 Effective Date”). The Amended Agreement provides Mr. Nathanielsz with a base salary of $ 600,000 414,900 100 200 Amended and Restated Employment Agreement On May 14, 2019, the Company entered into an Amended and Restated Services Agreement (the “Services Agreement”) with Dr. Kenyon, the Company’s Chief Scientific Officer and a director, for a term of three years 54,000 41,580 0.02 4,250,000 100 0.02 0.02 10 0.02 0.02 As of June 30, 2024 and 2023, total accrued salaries of $ 148,000 97,044 96,000 64,627 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 Intercompany Loans All intercompany loans were made by the parent to the Company’s subsidiary, Propanc PTY LTD, none of which has been repaid as of June 30, 2024. Effective fiscal year 2021, the parent company determined that intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment on the consolidated balance sheet as accumulated other comprehensive income.

CONCENTRATIONS AND RISKS

CONCENTRATIONS AND RISKS	12 Months Ended
	Jun. 30, 2024
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND RISKS	NOTE 11 – CONCENTRATIONS AND RISKS Concentration of Credit Risk The Company maintains its cash in banks and financial institutions in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through June 30, 2024. In fiscal 2023, the Company primarily relied on funding from five convertible debt lenders and received net proceeds after deductions of $ 79,111 101,250 189,000 150,000 50,000 100,000 17 32 25 8 18 In fiscal 2024, the Company primarily relied on funding from five convertible and non-convertible debt lenders and received net proceeds after deductions of $ 103,900 295,000 150,000 127,500 120,000 224,885 28 14 12 11 21 Receivable Concentration As of June 30, 2024 and 2023, the Company’s receivables were 100 Patent and Patent Concentration The Company has filed multiple patent applications relating to its lead product, PRP. The Company’s lead patent application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Republic of Korea, India and Brazil. In Canada and Mexico, the patent applications have been accepted as of fiscal year 2023. In 2016 and early 2017, the Company filed other patent applications. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications filed in November 2016, entered national phase in July 2018 and another PCT application entered national phase in August 2018. A third PCT application entered the national phase in October 2018. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 84 granted, allowed, or accepted patents and 6 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. Further patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer. Foreign Operations As of June 30, 2024 and 2023, the Company’s operations are based in Camberwell, Australia; however, the majority of research and development is being conducted in the European Union. On July 22, 2016, the Company formed a wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales, for the purpose of submitting an orphan drug application with the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2024 and 2023, there has been no activity within this entity. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	12 Months Ended
	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	NOTE 12 - DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company applies the provisions of ASC 815-40, Contracts in Entity’s Own Equity 110,500 75,300 The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at June 28, 2024, the last trading day of the period ended June 30, 2024, was $ 0.0013 Convertible Debt SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations into during the year ended June 30, 2024) Volatility 323.40 333.45 % Expected Remaining Term (in years) 0.50 Risk Free Interest Rate 5.42 5.55 % Expected dividend yield None June 30, 2024 June 30, 2023 Volatility 323.40 % 334.56 % Expected remaining term 0.01 0.28 0.01 0.73 Risk-free interest rate 5.45 5.47 % 5.24 % Expected dividend yield None None Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2024: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 133,886 $ — $ — $ 133,886 Total $ 133,886 $ — $ — $ 133,886 The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2023: Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 423,209 $ — $ — $ 423,209 Total $ 423,209 $ — $ — $ 423,209 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 The following is a roll forward for the years ended June 30, 2024 and 2023 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2022 $ 151,262 Initial fair value of embedded conversion option derivative liability recorded as debt discount 93,668 Gain on debt extinguishment (352,051 ) Change in fair value included in statements of operations 530,330 Balance at June 30, 2023 423,209 Initial fair value of embedded conversion option derivative liability recorded as debt discount 150,000 Initial fair value of embedded conversion option derivative liability recorded as derivative expense 141,012 Gain on debt extinguishment (263,798 ) Change in fair value included in statements of operations (316,537 ) Balance at June 30, 2024 $ 133,886

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 – SUBSEQUENT EVENTS Loans Payable – Related Party Effective August 1, 2024, the Company entered into and closed a loan agreement (the “Loan”) with an institutional investor affiliated with one of our directors, Josef Zelinger, pursuant to which the investor loaned the Company an aggregate principal amount of $ 150,000 97,649 November 1, 2024 12 18 35 Effective August 26, 2024, the Company entered into and closed a loan agreement with one of the members of the Board of Directors of the Company (the “Board Member”), pursuant to which the Board Member loaned the Company an aggregate principal amount of $ 85,000 57,638 Issuance of convertible notes GS Capital Partners, LLC Securities Purchase Agreement On August 2, 2024, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 33,000 3,000 The maturity date of the GS Capital Note is February 2, 2025 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0017 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.001 per share in the event that the market price of the Common Stock trades below $0.0014 per share for five consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. Pursuant to the Note, in the event that such conversion price is below the par value of the Common Stock, the Company has agreed to take all steps to reduce such par value or conduct a reverse split of its Common Stock, as applicable. Notwithstanding the foregoing, such conversion price and lookback periods are subject to adjustment in favor of the investor in the event the Company issues securities to another party with more favorable conversion terms, and such conversions are subject to a 4.99% beneficial ownership limitation (which may be increased to 9.9% upon 60 days’ prior written notice from the holder of the Note). The GS Capital note shall be bifurcated from the embedded conversion option which was recorded as derivative liabilities at fair value. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 During the first 60 to 180 days following the date of the above GS Capital notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to GS Capital, together with any other amounts that the Company may owe GS Capital under the terms of the notes, at a premium ranging from 110 125 Upon the occurrence and during the continuation of certain events of default, interest accrues at a default interest rate of 24 250 th 500 th 20 The above GS Capital note will be bifurcated from the embedded conversion option which shall be recorded as derivative liabilities at fair value. Shares issued for conversion of convertible debt From July 1, 2024 through September 19, 2024, the Company issued an aggregate of 209,219,529 0.0003 44,925 7,053 2,548 9,337 Consulting Agreement On August 12, 2024, the Company entered into a consulting agreement with two consultants to provide investor relation services from August 12, 2024 to October 12, 2024 for a total fee of $ 7,500 15,000,000 0.001 15,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 Proposed Reverse Stock Split (Unaudited) On August 7, 2024, the Company received written consent in lieu of a meeting by the holders of a majority of the voting power of the Company’s outstanding capital stock as of August 7, 2024 and the Company’s Board of Directors approving such actions as are necessary for the Company to proceed to, and the Company accordingly intends to, effectuate and execute a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio somewhere between one post-split share per ten thousand pre-split shares (1:10,000) and one post-split share per one hundred thousand pre-split shares (1:100,000) (the “Reverse Stock Split”) The unaudited pro forma tables below show the losses per share prior to the reverse split and following the reverse split. A key assumption to the loss per share calculation is that post-reverse split price is equal to the pre-reverse split times the number of shares from the ratio. SCHEDULE OF LOSS PER SHARE BASIS OF REVERSE STOCK SPLIT Historical per share data – (Pre- Split basis) Year Ended June 30, 2024 Year Ended June 30, 2023 Net loss available to Common Stockholders $ 2,013,488 $ 3,126,839 Basic and diluted weighted average shares outstanding 85,045,339 1,738,802 Basic and diluted net loss per share $ 0.02 $ 1.80 The assumption inherent in the table below is a reverse split of 1:100,000. Historical per share data – (Post- Split basis) Year Ended June 30, 2024 Year Ended June 30, 2023 Net loss available to Common Stockholders $ 2,013,488 $ 3,126,839 Basic and diluted weighted average shares outstanding 850 17 Basic and diluted net loss per share $ 2,368.81 $ 183,931.71 The table below shows the loss per share effect of reverse stock splits at 1:10,000, 1:50,000 and 1:100,000: Year Ended Year Ended Year Ended Year Ended Year Ended Year Ended Split Ratio 1:10,000 1:50,000 1:100,000 Year Ended Year Ended Year Ended Year Ended Year Ended Year Ended Net losses available to common stockholders $ 2,013,488 $ 3,126,839 $ 2,013,488 $ 3,126,839 $ 2,013,488 $ 3,126,839 Weighted Average Shares Outstanding 8,505 174 1,701 35 850 17 Loss per share $ 236.74 $ 17,970 $ 1,183.71 $ 89,338.26 $ 2,368.81 $ 183,931.71

Insider Trading Arrangement

Insider Trading Arrangement	12 Months Ended
	Jun. 30, 2024
Insider Trading Arrangement
No Insider Trading Flag	true

NATURE OF OPERATIONS AND SUMM_2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) is based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2024, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 84 granted, allowed, or accepted patents and 6 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand (1:1,000) The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through June 30, 2024 and remains inactive.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives of long-lived assets, valuation of the collectability of a refundable advance deposit, present value of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.
Foreign Currency Translation and Other Comprehensive Income (Loss)	Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly-owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency, which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency translations are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per Accounting Standards Codification (“ASC”) 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). As of June 30, 2024 and 2023, the Company recognized a cumulative exchange gain of approximately $ 90,000 648,000 As of June 30, 2024 and 2023, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES June 30, 2024 June 30, 2023 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6693 0.6664 Average exchange rate for the period USD : AUD exchange rate 0.6557 0.6732 Change in Accumulated Other Comprehensive Income (Loss) by component during the years ended June 30, 2024 and 2023 were as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Currency Items: Beginning balance, June 30, 2022 $ 1,234,549 Foreign currency translation gain 60,327 Balance, June 30, 2023 1,294,876 Foreign currency translation loss (25,295 ) Ending balance, June 30, 2024 $ 1,269,581
Fair Value of Financial Instruments and Fair Value Measurements	Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 12 - Derivative Financial Instruments and Fair Value Measurements.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts, as applicable, are reflected as a current liability on the balance sheets. There were no
Refundable Advance Deposit	Refundable Advance Deposit In August 2023, the Company paid a refundable advance deposit of $ 120,958 120,958
Deferred Offering Costs	Deferred Offering Costs The Company complies with the requirements of ASC 340, Other Assets and Deferred Costs, with regards to offering costs. Prior to the completion of an offering, offering costs are capitalized and consist principally of professional, underwriting and other expenses incurred through the balance sheet date that are directly related to the Company’s proposed public offering. The deferred offering costs are charged to additional paid-in capital or as a discount to debt, as applicable, upon the completion of an offering or to expense if the offering is not completed. As of June 30, 2024 and 2023 the Company had recorded $ 27,117 0
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Machinery and equipment - 5 Furniture - 7
Patents	Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through June 30, 2024 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023
Employee Benefit/Liability	Employee Benefit/Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months.
Australian Goods and Services Tax (“GST”)	Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of June 30, 2024 and 2023, the Company was owed $ 2,950 2,867
Derivative Instruments	Derivative Instruments ASC Topic 815, Derivatives and Hedging
Convertible Notes With Variable Conversion Options	Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of the Company’s common stock, par value $ 0.001 Distinguishing Liabilities from Equity
Income Taxes	Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes
Research and Development Costs and Tax Credits	Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 248,102 247,919 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as a tax benefit, in operations, upon receipt. During each of the fiscal years ended June 30, 2024 and 2023, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $ 129,132 129,841
Stock Based Compensation	Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption.
Revenue Recognition	Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun.
Legal Expenses	Legal Expenses All legal costs for litigation are charged to expense as incurred.
Leases	Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses.
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the convertible notes has agreed to a 4.99 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS June 30, 2024 June 30, 2023 Stock Options 0.06 0.06 Warrants with no designations 15,003,396 90 Series A Warrants as if converted at alternate cashless exercise prices 1,990,353,990 1,996,625,990 Series B Warrants 16 16 Series C Warrants as if converted at alternate cashless exercise prices * 9,175,999,954 9,473,999,953 Unvested restricted stock units 0.06 0.06 Convertible Debt 393,727,811 5,991,195 Total 11,575,085,167.12 11,476,617,244.12 * Only convertible ratably upon exercise of Series B Warrants
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term with the exception of those disclosed below. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The Company is currently assessing the impact the new guidance will have on its consolidated financial statements.

NATURE OF OPERATIONS AND SUMM_3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Tables)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SCHEDULE OF TRANSACTION EXCHANGE RATES	As of June 30, 2024 and 2023, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES June 30, 2024 June 30, 2023 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6693 0.6664 Average exchange rate for the period USD : AUD exchange rate 0.6557 0.6732
SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS	Change in Accumulated Other Comprehensive Income (Loss) by component during the years ended June 30, 2024 and 2023 were as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Currency Items: Beginning balance, June 30, 2022 $ 1,234,549 Foreign currency translation gain 60,327 Balance, June 30, 2023 1,294,876 Foreign currency translation loss (25,295 ) Ending balance, June 30, 2024 $ 1,269,581
SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES	The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Machinery and equipment - 5 Furniture - 7
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS June 30, 2024 June 30, 2023 Stock Options 0.06 0.06 Warrants with no designations 15,003,396 90 Series A Warrants as if converted at alternate cashless exercise prices 1,990,353,990 1,996,625,990 Series B Warrants 16 16 Series C Warrants as if converted at alternate cashless exercise prices * 9,175,999,954 9,473,999,953 Unvested restricted stock units 0.06 0.06 Convertible Debt 393,727,811 5,991,195 Total 11,575,085,167.12 11,476,617,244.12 * Only convertible ratably upon exercise of Series B Warrants

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	Property and equipment consist of the following as of June 30: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2024 2023 Office equipment at cost $ 25,543 $ 25,432 Less: Accumulated depreciation (25,543 ) (25,130 ) Total property, plant, and equipment $ - $ 302

NOTE PAYABLE AND CONVERTIBLE _2

NOTE PAYABLE AND CONVERTIBLE NOTES (Tables)	12 Months Ended
	Jun. 30, 2024
Note Payable And Convertible Notes
SCHEDULE OF CONVERTIBLE NOTES	The Company’s convertible notes outstanding at June 30, 2024 and 2023 were as follows: SCHEDULE OF CONVERTIBLE NOTES June 30, 2024 June 30, 2023 Convertible notes and debenture $ 313,550 $ 338,362 Unamortized discounts (38,854 ) (38,994 ) Premium, net 124,629 91,171 Convertible notes, net $ 399,325 $ 390,539

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
SCHEDULE OF INCOME TAX PROVISION	The reconciliation of income tax expense computed at the U.S. federal statutory rate of 21% to the income tax provision for the years ended June 30, 2024 and 2023 is as follows: PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 and 2023 SCHEDULE OF INCOME TAX PROVISION US June 30, 2024 June 30, 2023 Year Ended US June 30, 2024 June 30, 2023 Loss before Income taxes $ (1,874,914 ) $ (2,790,407 ) Taxes under statutory US tax rates $ (393,732 ) $ (585,986 ) Increase (decrease) in valuation allowance 306,682 556,521 Foreign tax rate differential (55,358 ) (60,316 ) Prior period adjustment 76,194 81,599 Other 66,214 8,182 Income tax (expense) benefit $ - $ -
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES June 30, 2024 June 30, 2023 Year Ended June 30, 2024 June 30, 2023 Deferred tax assets Warrant Derivative Liability $ 513,071 $ 579,544 Accrued Expenses 559,723 478,273 Prepaid Investor Services 551,796 575,021 Non-cash interest 817,536 758,797 Intangibles (Intellectual Property and Patent Cost) 351,144 321,557 Deferred Rent 4,492 4,550 Formation Expense 6,553 6,553 Net Operating Loss carryforward 9,075,029 8,910,874 Gain on extinguishment of debt 97,992 47,393 Stock Based Compensation 84,028 84,028 Total Deferred tax assets $ 12,061,364 $ 11,766,590 Deferred tax liabilities Research and Development $ (170,435 ) $ (202,568 ) Foreign Exchange Loss (OCI) (39,379 ) (39,379 ) Capital Raising Costs (389,258 ) (369,033 ) Total deferred tax liabilities $ (599,072 ) $ (610,980 ) Net deferred tax assets $ 11,462,292 $ 11,155,610 Valuation allowance (11,462,292 ) (11,155,610 ) Net deferred tax assets $ - $ -

STOCKHOLDERS_ DEFICIT (Tables)

STOCKHOLDERS’ DEFICIT (Tables)	12 Months Ended
	Jun. 30, 2024
Equity [Abstract]
SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY	A summary of the Company’s stock option activity during the years ended June 30, 2024 and 2023 is presented below: SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY Weighted Number of Average Options Price Per Share Outstanding at June 30, 2022 0.059 $ 4,533,000 Issued - - Exercised - - Expired - - Outstanding at June 30, 2023 0.059 $ 4,533,000 Issued - - Exercised - - Expired - - Outstanding at June 30, 2024 0.059 $ 4,533,000 Exercisable at June 30, 2024 0.059 $ 4,533,000 Outstanding and Exercisable: Weighted average remaining contractual term 4.87 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ -
SCHEDULE OF WARRANT ACTIVITY	The following table summarizes common stock warrant activity for the years ended June 30, 2024 and 2023: SCHEDULE OF WARRANT ACTIVITY Weighted Number of Average Warrants Price Per Share Outstanding at June 30, 2022 105 $ 200,270 Issued 3,305 10 Exercised (13 ) 52,081 Forfeited (1 ) 2,000,000 Expired - - Outstanding at June 30, 2023 3,396 $ 5,440 Issued 15,000,000 0.01 Exercised - - Forfeited - - Expired - - Outstanding at June 30, 2024 15,003,396 * $ 1.24 Exercisable at June 30, 2024 15,003,378 $ 1.24 Outstanding and Exercisable: Weighted average remaining contractual term 2.01 Aggregate intrinsic value $ - * The total warrants of 15,003,396
SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE	SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 10 10 Series B warrants 17 17 Series C warrants 64 46 Common stock warrants with no class designation 15,003,305 15,003,305 Total 15,003,396 15,003,378

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF RIGHT OF USE ASSET	ROU is summarized below: SCHEDULE OF RIGHT OF USE ASSET June 30, 2024 June 30, 2023 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (48,402 ) (27,213 ) Right-of-use asset, net $ 17,799 $ 38,988
SCHEDULE OF OPERATING LEASE LIABILITY	Operating Lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY June 30, 2024 June 30, 2023 Office lease $ 66,201 $ 66,201 Reduction of lease liability (46,839 ) (25,418 ) Less: office lease, current portion (19,362 ) (21,505 ) Long term portion of lease liability $ - $ 19,278
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS	Remaining future minimum lease payments under non-cancelable operating lease at June 30, 2024 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2025 $ 20,079 Imputed interest (717 ) Total operating lease liability $ 19,362

DERIVATIVE FINANCIAL INSTRUME_2

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES	SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations into during the year ended June 30, 2024) Volatility 323.40 333.45 % Expected Remaining Term (in years) 0.50 Risk Free Interest Rate 5.42 5.55 % Expected dividend yield None June 30, 2024 June 30, 2023 Volatility 323.40 % 334.56 % Expected remaining term 0.01 0.28 0.01 0.73 Risk-free interest rate 5.45 5.47 % 5.24 % Expected dividend yield None None
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS	SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 133,886 $ — $ — $ 133,886 Total $ 133,886 $ — $ — $ 133,886 The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2023: Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 423,209 $ — $ — $ 423,209 Total $ 423,209 $ — $ — $ 423,209
SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE	The following is a roll forward for the years ended June 30, 2024 and 2023 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2022 $ 151,262 Initial fair value of embedded conversion option derivative liability recorded as debt discount 93,668 Gain on debt extinguishment (352,051 ) Change in fair value included in statements of operations 530,330 Balance at June 30, 2023 423,209 Initial fair value of embedded conversion option derivative liability recorded as debt discount 150,000 Initial fair value of embedded conversion option derivative liability recorded as derivative expense 141,012 Gain on debt extinguishment (263,798 ) Change in fair value included in statements of operations (316,537 ) Balance at June 30, 2024 $ 133,886

SUBSEQUENT EVENTS (Tables)

SUBSEQUENT EVENTS (Tables)	12 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SCHEDULE OF LOSS PER SHARE BASIS OF REVERSE STOCK SPLIT	The unaudited pro forma tables below show the losses per share prior to the reverse split and following the reverse split. A key assumption to the loss per share calculation is that post-reverse split price is equal to the pre-reverse split times the number of shares from the ratio. SCHEDULE OF LOSS PER SHARE BASIS OF REVERSE STOCK SPLIT Historical per share data – (Pre- Split basis) Year Ended June 30, 2024 Year Ended June 30, 2023 Net loss available to Common Stockholders $ 2,013,488 $ 3,126,839 Basic and diluted weighted average shares outstanding 85,045,339 1,738,802 Basic and diluted net loss per share $ 0.02 $ 1.80 The assumption inherent in the table below is a reverse split of 1:100,000. Historical per share data – (Post- Split basis) Year Ended June 30, 2024 Year Ended June 30, 2023 Net loss available to Common Stockholders $ 2,013,488 $ 3,126,839 Basic and diluted weighted average shares outstanding 850 17 Basic and diluted net loss per share $ 2,368.81 $ 183,931.71 The table below shows the loss per share effect of reverse stock splits at 1:10,000, 1:50,000 and 1:100,000: Year Ended Year Ended Year Ended Year Ended Year Ended Year Ended Split Ratio 1:10,000 1:50,000 1:100,000 Year Ended Year Ended Year Ended Year Ended Year Ended Year Ended Net losses available to common stockholders $ 2,013,488 $ 3,126,839 $ 2,013,488 $ 3,126,839 $ 2,013,488 $ 3,126,839 Weighted Average Shares Outstanding 8,505 174 1,701 35 850 17 Loss per share $ 236.74 $ 17,970 $ 1,183.71 $ 89,338.26 $ 2,368.81 $ 183,931.71

SCHEDULE OF TRANSACTION EXCHANG

SCHEDULE OF TRANSACTION EXCHANGE RATES (Details)	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6693	0.6664
Weighted Average [Member]
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6557	0.6732

SCHEDULE OF ACCUMULATED OTHER C

SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Accounting Policies [Abstract]
Beginning balance	$ 1,294,876	$ 1,234,549
Foreign currency translation, gain	(25,295)	60,327
Ending balance	$ 1,269,581	$ 1,294,876

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES (Details)	Jun. 30, 2024
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment	7 years

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS (Details) - shares		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		11,575,085,167.12	11,476,617,244.12
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		0.06	0.06
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		15,003,396	90
Series A Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		1,990,353,990	1,996,625,990
Series B Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		16	16
Series C Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	[1]	9,175,999,954	9,473,999,953
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		0.06	0.06
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		393,727,811	5,991,195
[1]Only convertible ratably upon exercise of Series B Warrants

NATURE OF OPERATIONS AND SUMM_4

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Details Narrative) - USD ($)		12 Months Ended
	May 01, 2023	Jun. 30, 2024	Jun. 30, 2023	Aug. 31, 2023
Accounting Policies [Abstract]
Reverse stock split	one-for-one thousand (1:1,000)
Foreign currency transaction, gain		$ 90,000	$ 648,000
Cash and cash equivalents		0	0
Refundable advance deposit				$ 120,958
Allowance for recoverability of refundable advance deposit		120,958
Deferred offering cost		27,117
GST tax receivable		$ 2,950	$ 2,867
Common stock, par value		$ 0.001	$ 0.001
Research and development costs		$ 248,102	$ 247,919
Research and development tax credit		$ 129,132	$ 129,841
Beneficial ownership conversion description		Each holder of the convertible notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance
Beneficial ownership percentage		4.99%

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 1,820,528	$ 2,660,566
Net cash used in operations	935,118	1,105,251
Working capital deficit	3,767,341
Stockholders' deficit	3,779,059	3,117,179	$ 3,023,649
Accumulated deficit	$ 66,698,220	$ 64,684,732

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Office equipment at cost	$ 25,543	$ 25,432
Less: Accumulated depreciation	(25,543)	(25,130)
Total property, plant, and equipment		$ 302

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation	$ 297	$ 1,665

DUE TO FORMER DIRECTOR - RELA_2

DUE TO FORMER DIRECTOR - RELATED PARTY (Details Narrative) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Former Director [Member]
Defined Benefit Plan Disclosure [Line Items]
Due to related parties current	$ 29,759	$ 29,630

LOANS (Details Narrative)

LOANS (Details Narrative)						1 Months Ended		12 Months Ended
	Jul. 05, 2023 USD ($) $ / shares shares	Nov. 03, 2022 USD ($)	Nov. 03, 2022 USD ($)	Aug. 16, 2022 USD ($) $ / shares	Oct. 03, 2019 USD ($)	Jun. 30, 2024 USD ($) $ / shares	Jul. 31, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 AUD ($)	May 31, 2024 USD ($)	Nov. 30, 2023 AUD ($)	Jul. 05, 2023 AUD ($)	Jun. 30, 2022 USD ($)	Nov. 30, 2020 USD ($)
Debt instrument face amount						$ 130,800		$ 130,800	$ 168,200			$ 71,629
Debt instrument interest rate stated percentage	10%												10%
Settlement of convertible debt								142,909
Interest payable current and non current						8,700		8,700	16,632
Amortization of debt discounts								294,005	202,952
Debt remaining						313,550		313,550	338,362
Remaining debt discount						38,854		38,854	38,994
Gain on extinguishment of debt								54,565	25,969
Crown Bridge Partners, LLC [Member]
Debt instrument face amount						$ 65,280		$ 65,280
Debt instrument interest rate stated percentage						15%		15%		15%
Interest payable current and non current						$ 45,541		$ 45,541
Warrant [Member]
Fair value adjustment of warrants				$ 2,408
Stock valuation price per share | $ / shares				$ 2.60		$ 0.119		$ 0.119
Warrant exercise price | $ / shares				$ 10				$ 0.01
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement input				0		0		0		0
Warrant [Member] | Measurement Input, Expected Term [Member]
Maturity term				3 years
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement input				3.19		4.59		4.59		4.59
Warrant [Member] | Measurement Input, Price Volatility [Member]
Measurement input				236		268		268		268
Letter Agreement [Member]
Debt instrument face amount	$ 153,256												$ 230,000
Maturity term	3 years
Maturity date	Jul. 05, 2026
Debt instrument interest rate stated percentage	10%												10%
Issue of warrants | shares	15,000,000
Share price | $ / shares	$ 0.01
Fair value adjustment of warrants	$ 141,084
Debt instrument maturity date						June 2025
Letter Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Settlement of convertible debt								$ 143,000
Letter Agreement [Member] | Warrant [Member]
Stock valuation price per share | $ / shares	$ 0.119
Warrant exercise price | $ / shares	$ 0.01
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement input	0												0
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Expected Term [Member]
Maturity term	3 years
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement input	4.59												4.59
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Price Volatility [Member]
Measurement input	268												268
Securities Purchase Agreement [Member]
Debt instrument face amount									65,280
Maturity date					Oct. 03, 2020
Amortization of debt discounts								232,700	210,278
Securities Purchase Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Debt instrument face amount		$ 125,000	$ 125,000				$ 142,909
Debt instrument interest rate stated percentage		10%	10%
Settlement of convertible debt							142,979
Interest payable current and non current							$ 70		22,749
Amortization of debt discounts		$ 37,500	$ 37,500
Remaining debt discount		$ 25,000	$ 25,000
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Debt instrument face amount						$ 65,280		65,280	65,280					$ 65,280	$ 9,600
Maturity date					Oct. 03, 2020
Debt instrument interest rate stated percentage					15%
Interest payable current and non current						45,541		45,541	35,722					$ 25,930
Remaining debt discount					$ 5,000
Convertible debt						65,280		65,280
Gain on extinguishment of debt									43,520
Loan Agreement [Member]
Loans payable						145,091		145,091	65,280
Debt instrument face amount						$ 79,811		$ 79,811		$ 120,000
Debt instrument interest rate stated percentage						12%		12%		12%
Interest payable current and non current						$ 665		$ 665
Debt remaining						79,811		79,811
Related Party [Member]
Loans payable						49,528		49,528	49,314
Loan payable						71,629		71,629			$ 71,629
Interest payable current and non current						15,158		15,158
Amortization of debt discounts								46,470
Debt remaining						153,256		153,256
Remaining debt discount						94,614		94,614
Loan payable - long-term - related party, net of discount						$ 58,642		$ 58,642

SCHEDULE OF CONVERTIBLE NOTES (

SCHEDULE OF CONVERTIBLE NOTES (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Note Payable And Convertible Notes
Convertible notes and debenture	$ 313,550	$ 338,362
Unamortized discounts	(38,854)	(38,994)
Premium, net	124,629	91,171
Convertible notes, net	$ 399,325	$ 390,539

NOTE PAYABLE AND CONVERTIBLE _3

NOTE PAYABLE AND CONVERTIBLE NOTES (Details Narrative)																													1 Months Ended		12 Months Ended
	Jan. 15, 2025 USD ($)	Dec. 30, 2024 USD ($)	Dec. 15, 2024 USD ($)	Nov. 30, 2024 USD ($)	Jun. 20, 2024 USD ($)	Jun. 10, 2024 USD ($)	May 24, 2024 USD ($)	Apr. 12, 2024 USD ($)	Mar. 05, 2024 USD ($)	Dec. 08, 2023 USD ($)	Nov. 29, 2023 USD ($)	Oct. 20, 2023 USD ($)	Oct. 12, 2023 USD ($)	Aug. 23, 2023 USD ($)	Aug. 16, 2023 USD ($)	Aug. 15, 2023 USD ($)	Jul. 19, 2023 USD ($)	Jul. 06, 2023 USD ($)	Feb. 14, 2023 USD ($)	Nov. 03, 2022 USD ($) shares	Nov. 03, 2022 USD ($) shares	Oct. 06, 2022 USD ($)	Sep. 21, 2022 USD ($)	Aug. 15, 2022 USD ($)	Aug. 12, 2022 USD ($)	Jul. 11, 2022 USD ($)	Sep. 16, 2020 shares	Oct. 03, 2019 USD ($)	Aug. 31, 2023	Jul. 31, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2020 USD ($)	Jun. 11, 2024 shares	May 04, 2024	Feb. 20, 2024 shares	Dec. 13, 2023 shares	Nov. 30, 2023 AUD ($)	Jul. 05, 2023	Jun. 30, 2022 USD ($)	Nov. 30, 2020 USD ($)
Principal amount																															$ 130,800	$ 168,200						$ 71,629
Debt instrument interest rate percentage																																							10%
Accrued interest																															8,700	16,632
Amortization of debt discount																															294,005	202,952
Debt remaining																															313,550	338,362
Original issue discount																															38,854	38,994
Note payable, net of discount																															204,694
Proceeds from convertible debt																															567,050	590,250
Debt instrument default interest rate								24%
Debt premium																															124,629	91,171
Gain on extinguishment of debt																															54,565	25,969
Penalty amount																															$ 30,000
Conversion price percentage																															4.99%
Derivative liabilities																															$ 133,886	423,209
Fee amount																															3,832	1,838
Number of shares issued | shares																																		15,768,400		1,755,240	1,390,008
Additional debt issued																															773,548	1,387,723
Settlement of convertible debt																															142,909
Conversion of stock amount converted																															246,254	411,111
Maximum [Member]
Debt instrument interest rate percentage																																			8%
Securities Purchase Agreement [Member]
Principal amount																																65,280
Debt instrument maturity date																												Oct. 03, 2020
Amortization of debt discount																															232,700	210,278
Debt premium																															279,711	232,674
Red Road Holdings Securities Purchase Agreement [Member]
Principal amount																						$ 53,750
Debt instrument interest rate percentage																						8%
Debt Instrument description																						The Red Road Note may be prepaid until 180 days from its issuance date, subject to the following: if prepaid within 60 days of the issuance date, the prepayment premium is 110% of the face amount of such note plus any accrued interest, if prepaid after 60 days but less than 91 days from the issuance date, then the prepayment premium is 115% of the face amount plus any accrued interest of such note., if prepaid after 90 days but less than 121 days from the issuance date, then the prepayment premium is 120% of the face amount plus any accrued interest of such note, if prepaid after 120 days but less than 151 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest of such note, and if prepaid after 150 days but less than 181 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest of such note
Monthly payment amount																																0
Principal amount																																2,150
Debt instrument conversion rate																						65%
Debt instrument discount rate																						35%
Ownership limitations																						4.99%
Principal amount																																53,750
Proceeds from convertible debt																						$ 50,000
Debt instrument default interest rate																						22%
Debt premium																						$ 28,942										28,942
Penalty amount																						1,000
Legal fees																						$ 3,750
Convertible Notes One [Member]
Amortization of debt discount																															$ 294,005	202,952
1800 Diagonal Lending LLC [Member]
Debt instrument original issue discount rate						15%	15%																								150%
Original issue discounts amount						$ 8,200	$ 8,200
Principal amount						$ 49,200	$ 49,200
Debt instrument interest rate percentage						22%	22%
Accrued interest																															$ 1,193
Debt remaining																															$ 98,400
Legal and financing costs						$ 6,000	$ 6,000
Net proceeds						$ 35,000	$ 35,000
Debt instrument conversion rate																															65%
Debt instrument discount rate																															35%
Ownership limitations																															4.99%
1800 Diagonal Lending LLC [Member] | Securities Purchase Agreement [Member]
Principal amount																															$ 0
Debt instrument interest rate percentage											8%
Debt instrument default interest rate											35%
Debt premium																															134,615
Convertible debt principal amount																															250,000
Percentage of outstanding shares of common stock											150%
Debt instrument settlement debt amount											$ 134,615
Debt outstanding principal percentage											22%
Penalty amount											$ 1,000
Accrued interest																															9,863
1800 Diagonal Lending LLC [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Debt instrument default interest rate											110%
1800 Diagonal Lending LLC [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Debt instrument default interest rate											129%
Percentage of outstanding shares of common stock											9.99%
1800 Diagonal Lending LLC [Member] | July11, 2022 1800 Diagonal Note [Member] | Securities Purchase Agreement [Member]
Principal amount																										$ 105,000
Debt instrument maturity date																										Jun. 30, 2023
Debt instrument interest rate percentage																										8%
Debt issuance costs																										$ 3,750
1800 Diagonal Lending LLC [Member] | July 6, 2023 1800 Diagonal Note [Member] | Securities Purchase Agreement [Member]
Principal amount																		$ 65,000
Debt instrument maturity date																		Jun. 29, 2024
Debt issuance costs																		$ 5,000
1800 Diagonal Lending LLC [Member] | July 19, 2023 1800 Diagonal Note [Member] | Securities Purchase Agreement [Member]
Principal amount																	$ 45,000
Debt instrument maturity date																	Jul. 19, 2024
Debt issuance costs																	$ 5,000
1800 Diagonal Lending LLC [Member] | August 16, 2023 1800 Diagonal Note [Member] | Securities Purchase Agreement [Member]
Principal amount															$ 55,000
Debt instrument maturity date															Aug. 16, 2024
Debt issuance costs															$ 5,000
1800 Diagonal Lending LLC [Member] | October 20, 2023 1800 Diagonal Note [Member] | Securities Purchase Agreement [Member]
Principal amount												$ 40,000
Debt instrument maturity date												Oct. 20, 2024
Debt issuance costs												$ 5,000
1800 Diagonal Lending LLC [Member] | November 29, 2023 1800 Diagonal Note [Member] | Securities Purchase Agreement [Member]
Principal amount											$ 45,000
Debt instrument maturity date											Sep. 15, 2024
Debt issuance costs											$ 5,000
1800 Diagonal Lending LLC [Member] | Forecast [Member]
Monthly payment amount				$ 28,290
Principal amount	$ 7,072.50	$ 7,072.50		7,072.50
Payment of debt				$ 56,580
Crown Bridge Partners, LLC [Member]
Principal amount																															$ 65,280
Debt instrument interest rate percentage																															15%
Accrued interest																															$ 45,541
Crown Bridge Partners, LLC [Member] | Securities Purchase Agreement [Member]
Principal amount																															65,280	65,280								$ 65,280	$ 9,600
Debt instrument maturity date																												Oct. 03, 2020
Debt instrument interest rate percentage																												15%
Debt Instrument description																												The conversion price of the Crown Bridge Note was equal to 60% (representing a 40% discount) of the lowest closing bid price of the common stock for the ten trading days immediately prior to the delivery of a notice of conversion under such note, including the day upon which such notice was received subject to 4.99% or 9.99% beneficial ownership limitations
Accrued interest																															45,541	35,722								$ 25,930
Original issue discount																												$ 5,000
Proceeds from convertible debt																												100,000
Debt premium																												$ 72,000				13,889									6,400
Unissued shares conversion | shares																											15
Equity conversion																																									$ 16,000
Gain on extinguishment of debt																																43,520
Crown Bridge Partners, LLC [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Ownership limitations																												4.99%
Debt instrument default interest rate																												110%
Crown Bridge Partners, LLC [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Ownership limitations																												9.99%
Debt instrument default interest rate																												150%
Crown Bridge Partners, LLC [Member] | Crown Bridge Financing Agreement [Member]
Debt remaining																																0
Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member] | Securities Purchase Agreement [Member]
Principal amount																												$ 108,000
Debt remaining																																	$ 65,280
Principal amount																												$ 3,000
Crown Bridge Partners, LLC [Member] | August 2019 Auctus Note [Member] | Securities Purchase Agreement [Member]
Accrued interest																																	7,232
Debt premium																																	28,480
Convertible debt principal amount																																	$ 42,720
ONE44 Capital LLC [Member]
Accrued interest																															9,909	24,255
Debt premium																															100,000	133,305
ONE44 Capital LLC [Member] | Securities Purchase Agreement [Member]
Principal amount										$ 150,000									$ 111,111					$ 110,000							119,300	118,111
Debt instrument maturity date																								Aug. 15, 2022
Debt instrument interest rate percentage										10%									10%					10%
Accrued interest																															6,726	4,726
Original issue discount										$ 15,000									$ 11,111					$ 10,000
Ownership limitations										4.99%
Debt premium																															98,311	182,376
Convertible debt principal amount																															148,811	338,700
Debt outstanding principal percentage										24%
Legal fees										$ 7,500									$ 5,500					$ 5,500
Debt instrument increase principal percentage										20%
ONE44 Capital LLC [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Debt instrument conversion rate										60%
Debt instrument discount rate										35%
Debt instrument default interest rate										120%
Penalty amount										$ 250
ONE44 Capital LLC [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Debt instrument conversion rate										65%
Debt instrument discount rate										40%
Debt instrument default interest rate										135%
Penalty amount										$ 500
GS Capital Partners, LLC [Member]
Accrued interest																															8,700	2,945
Derivative fixed interest rate																															1,254
GS Capital Partners, LLC [Member] | Securities Purchase Agreement [Member]
Principal amount								$ 27,500					$ 61,000	$ 77,500									$ 71,500		$ 93,000						83,000
Debt instrument maturity date								Oct. 12, 2024					Apr. 12, 2024	Feb. 23, 2024									Mar. 21, 2023		Apr. 12, 2023
Debt instrument interest rate percentage								8%					8%	8%									8%		8%
Accrued interest																															8,364	4,263
Debt remaining																															$ 110,500	75,300
Original issue discount								$ 2,500					$ 3,500	$ 5,000									$ 4,000		$ 5,000
Net proceeds																							$ 65,000		$ 85,000
Debt instrument conversion rate								60%
Debt instrument discount rate								40%
Ownership limitations																							4.99%		4.99%						4.99%
Debt instrument default interest rate																															24%
Legal fees													$ 2,500	$ 2,500									$ 2,500		$ 3,000
Debt instrument increase principal percentage								20%
Conversion price, description								The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0017 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.001 per share in the event that the market price of the Common Stock trades below $0.0014 per share for five consecutive trading days					The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.015 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.01 per share in the event that the market price of the Common Stock trades below $0.0075 per share for ten consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default	The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.04 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.02 per share in the event that the market price of the Common Stock trades below $0.03 per share for five consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default									Such note was exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2 (the “September Fixed Price”). However, in the event the common stock trades below $1.40 per share for more than five consecutive trading days, then the September Fixed Price becomes $0.90 per share		The GS Capital Note was exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital by surrendering the same. GS Capital was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2.80 per share (the “Fixed Price”). However, in the event the common stock trades below $2 per share for more than five consecutive trading days, then the Fixed Price becomes $1.30 per share
Conversion price percentage																							65%		65%
Derivative liabilities																															$ 110,500	75,300
Fee amount																															3,832
GS Capital Partners, LLC [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Debt instrument default interest rate								110%
Penalty amount								$ 250
GS Capital Partners, LLC [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Debt instrument default interest rate								125%
Penalty amount								$ 500
GS Capital Partners, LLC [Member] | August 10, 2017 Consulting Agreement [Member]
Convertible debt principal amount																															130,800	89,200
Coventry Enterprises LLC Securities Purchase Agreement [Member]
Monthly payment amount																				$ 19,643
Coventry Enterprises LLC Securities Purchase Agreement [Member] | Securities Purchase Agreement [Member]
Principal amount																				$ 125,000	$ 125,000									$ 142,909
Debt instrument interest rate percentage																				10%	10%
Accrued interest																														70		22,749
Amortization of debt discount																				$ 37,500	$ 37,500
Original issue discount																				25,000	25,000
Proceeds from convertible debt																				100,000
Debt premium																															13,328
Convertible debt principal amount																				125,000
Debt instrument guaranteed interest																				$ 12,500	$ 12,500
Number of shares issued | shares																				75,000	75,000
Debt Default penalty																																25,000
Amount of convertible debt outstanding with penalty																															0	144,951
Amount repaid for covertible debt																															2,043	5,049
Additional debt issued																																$ 561
Settlement of convertible debt																														$ 142,979
Interest payable current and non current																															357
104 LLC [Member] | Securities Purchase Agreement [Member]
Principal amount					$ 33,750				$ 50,000
Debt instrument maturity date					Jun. 20, 2025				Mar. 01, 2025
Debt Instrument description					the Company has the right to prepay the principal and accrued but unpaid interest due under the notes, at a one hundred ten percent (110%) premium of the face amount plus accrued and unpaid interest, which increases to (i) one hundred fifteen percent (115%) if prepaid after 60 days, but less than 91 days from the issuance date, (ii) one hundred twenty percent (120%) if prepaid after 90 days, but less than 121 days from the issuance date, (iii) one hundred twenty five percent (125%) if prepaid after 120 days, but less than 181 days from the issuance date. After this initial 180-day period, the Company does not have a right to prepay the notes
Accrued interest																															1,429
Debt remaining																															83,750
Original issue discount					$ 3,375				$ 3,125
Legal and financing costs					$ 5,200				7,500
Debt instrument conversion rate					65%
Debt instrument discount rate					35%
Ownership limitations					4.99%
Debt premium																															45,096
Purchase amount					$ 30,375				$ 46,875
104 LLC [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Debt instrument interest rate percentage					8%				8%
104 LLC [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Debt instrument interest rate percentage					16%				16%
Loans Payable [Member]
Debt instrument original issue discount rate																10%
Original issue discounts amount																$ 120,000
Principal amount																$ 132,000
Debt instrument maturity date																Nov. 15, 2023
Debt instrument interest rate percentage																10%
Debt instrument increase interest rate																18%
Debt Instrument description																The Company had the right to prepay the principal and accrued but unpaid interest due under the Promissory Note, together with any other amounts that the Company may owe the August 2023 Lender under the terms of the Promissory Note, on or before September 14, 2023 at a 110% premium of the face amount plus accrued and unpaid interest and any other amounts owed to the August 2023 Lender, which increases to (i) 120% if prepaid after such date, but on or before October 14, 2023, and (ii) 130% if prepaid after October 14, 2023 (including on the maturity date), unless the Company and the Lender agree to otherwise effect repayment
Debt instrument interest rate																													130%
Accrued interest																															15,536
Amortization of debt discount																															12,000
Debt remaining																															132,000
Original issue discount																															0
Note payable, net of discount																															132,000
Loans Payable [Member] | Promissory Note [Member]
Debt remaining																															204,694
Original issue discount																															25,706
Loans Payable [Member] | 1800 Diagonal Lending LLC [Member]
Monthly payment amount			$ 28,290
Principal amount			7,072.50
Payment of debt			$ 56,580
Convertible Notes Payable [Member]
Convertible note																															$ 83,000
Maturity date description																															maturity dates between February 23, 2024 and April 12, 2024

SCHEDULE OF INCOME TAX PROVISIO

SCHEDULE OF INCOME TAX PROVISION (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income tax (expense) benefit	$ (129,132)	$ (129,841)
UNITED STATES
Loss before Income taxes	(1,874,914)	(2,790,407)
Taxes under statutory US tax rates	(393,732)	(585,986)
Increase (decrease) in valuation allowance	306,682	556,521
Foreign tax rate differential	(55,358)	(60,316)
Prior period adjustment	76,194	81,599
Other	66,214	8,182
Income tax (expense) benefit

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Warrant Derivative Liability	$ 513,071	$ 579,544
Accrued Expenses	559,723	478,273
Prepaid Investor Services	551,796	575,021
Non-cash interest	817,536	758,797
Intangibles (Intellectual Property and Patent Cost)	351,144	321,557
Deferred Rent	4,492	4,550
Formation Expense	6,553	6,553
Net Operating Loss carryforward	9,075,029	8,910,874
Gain on extinguishment of debt	97,992	47,393
Stock Based Compensation	84,028	84,028
Total Deferred tax assets	12,061,364	11,766,590
Research and Development	(170,435)	(202,568)
Foreign Exchange Loss (OCI)	(39,379)	(39,379)
Capital Raising Costs	(389,258)	(369,033)
Total deferred tax liabilities	(599,072)	(610,980)
Net deferred tax assets	11,462,292	11,155,610
Valuation allowance	(11,462,292)	(11,155,610)
Net deferred tax assets

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)		12 Months Ended
	Mar. 27, 2020	Jun. 30, 2024	Jun. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Tax benefit		$ (129,132)	$ (129,841)
Operating loss carryforwards		$ 10,600,000
Income tax rate		25%	25%
Unrecognized tax benefits		$ 0	$ 0
Changes in unrecognized tax benefits		0	0
UNITED STATES
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Tax benefit
Operating loss carryforwards		10,601,740
AUSTRALIA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Tax benefit		0	$ 0
Operating loss carryforwards		27,394,654
Operating loss carryforwards not expires		3,400,000
AUSTRALIA | Expire In Two Thousand Twenty Four [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating loss carryforwards expires		$ 7,200,000
Cares Act [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Income tax examination, description	The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative 2) - USD ($)	Jun. 11, 2024	Feb. 20, 2024	Jan. 31, 2024	Dec. 13, 2023
Equity [Abstract]
Shares, issued	15,768,400	1,755,240		1,390,008
Shares, issued average price per share	$ 0.0008	$ 0.0013		$ 0.006
Subscription receivable	$ 11,975	$ 2,260	$ 8,822	$ 8,822

STOCKHOLDERS_ DEFICIT (Detail_2

STOCKHOLDERS’ DEFICIT (Details Narrative 3) - USD ($)	1 Months Ended	12 Months Ended
	May 31, 2019	Jun. 30, 2024	Jun. 30, 2023
Restricted Stock Units (RSUs) [Member]
Restricted stock units, shares	0.117
Fair value granted, shares	$ 497,240
Unrecognized restricted stock units expense		$ 248,620	$ 248,620
Restricted stock units not yet vested, shares		$ 248,620	$ 248,620
Unvested Restricted Stock Units [Member]
Unvested restricted stock units		0.06	0.06
Chief Executive Officer [Member]
Restricted stock units, shares	0.078
Chief Scientific Officer [Member]
Restricted stock units, shares	0.039

SCHEDULE OF SHARE BASED COMPENS

SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Equity [Abstract]
Number of Shares, Outstanding, Balance	0.059	0.059
Weighted Average Price Per Share, Outstanding, Balance	$ 4,533,000	$ 4,533,000
Number of Shares, Issued
Weighted Average Price Per Share, Granted
Number of Shares, Exercised
Weighted Average Price Per Share, Exercised
Number of Shares, Expired
Weighted Average Price Per Share, Expired
Number of Shares, Outstanding, Balance	0.059	0.059
Weighted Average Price Per Share, Outstanding, Ending balance	$ 4,533,000	$ 4,533,000
Number of Shares, Exercisable, Balance	0.059
Weighted Average Price Per Share, Exercisable, Balance	$ 4,533,000
Weighted average remaining contractual term	4 years 10 months 13 days
Weighted average fair value of options granted during the period
Aggregate intrinsic value

STOCKHOLDERS_ DEFICIT (Detail_3

STOCKHOLDERS’ DEFICIT (Details Narrative 4) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Company recognized stock-based compensation	$ 0	$ 0
Unvested stock option expense	$ 0
Stock options granted	0	0
2019 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of common shares reserved for future issuance	234

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024		Jun. 30, 2023
Equity [Abstract]
Number of Shares, Outstanding, Balance	3,396		105
Weighted Average Price Per Share, Outstanding, Balance	$ 5,440		$ 200,270
Number of Shares, Granted	15,000,000		3,305
Weighted Average Price Per Share, Issued	$ 0.01		$ 10
Number of Shares, Exercised			(13)
Weighted Average Price Per Share, Exercised			$ 52,081
Number of Shares, Forfeited			(1)
Weighted Average Price Per Share, Forfeited			$ 2,000,000
Number of Shares, Expired
Weighted Average Price Per Share, Expired
Number of Shares, Exercised			13
Number of Shares, Forfeited			1
Number of Shares, Expired
Number of Shares, Outstanding, Balance	15,003,396	[1]	3,396
Weighted Average Price Per Share, Outstanding, Ending balance	$ 1.24		$ 5,440
Number of Shares, Exercisable, Balance	15,003,378
Weighted Average Price Per Share, Exercisable, Balance	$ 1.24
Weighted average remaining contractual term	2 years 3 days
Aggregate intrinsic value
[1]The total warrants of 15,003,396

SCHEDULE OF WARRANT ACTIVITY _2

SCHEDULE OF WARRANT ACTIVITY (Details) (Parenthetical) - shares	Jun. 30, 2024		Jun. 30, 2023	Jun. 30, 2022
Equity [Abstract]
Number of Shares, Outstanding, Balance	15,003,396	[1]	3,396	105
[1]The total warrants of 15,003,396

SCHEDULE OF WARRANT OUTSTANDING

SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE (Details) - shares	Jun. 30, 2024		Jun. 30, 2023	Jun. 30, 2022
Class of Stock [Line Items]
Number of Warrants, Total	15,003,396	[1]	3,396	105
Exercisable, Total	15,003,378
Series A Warrants [Member]
Class of Stock [Line Items]
Number of Warrants, Total	10
Exercisable, Total	10
Series B Warrants [Member]
Class of Stock [Line Items]
Number of Warrants, Total	17
Exercisable, Total	17
Series C Warrants [Member]
Class of Stock [Line Items]
Number of Warrants, Total	64
Exercisable, Total	46
Common Stock Warrants With No Class Designation [Member]
Class of Stock [Line Items]
Number of Warrants, Total	15,003,305
Exercisable, Total	15,003,305
[1]The total warrants of 15,003,396

STOCKHOLDERS_ DEFICIT (Detail_4

STOCKHOLDERS’ DEFICIT (Details Narrative)																1 Months Ended	12 Months Ended
	Jul. 20, 2023 USD ($) $ / shares	Jul. 10, 2023 shares	Jul. 05, 2023 USD ($) $ / shares shares	May 01, 2023	Mar. 08, 2023 USD ($) shares	Nov. 16, 2022 USD ($) $ / shares shares	Nov. 16, 2022 $ / shares shares	Nov. 03, 2022 USD ($) shares	Nov. 03, 2022 USD ($) shares	Oct. 25, 2022 USD ($) $ / shares shares	Aug. 16, 2022 USD ($) $ / shares shares	Jul. 13, 2022 USD ($) $ / shares shares	Nov. 30, 2021 USD ($)	Apr. 03, 2020 $ / shares shares	Mar. 20, 2020 Integer $ / shares shares	May 31, 2019 $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 11, 2024 USD ($) $ / shares shares	May 04, 2024	Feb. 20, 2024 USD ($) $ / shares shares	Jan. 31, 2024 USD ($)	Dec. 13, 2023 USD ($) $ / shares shares	Nov. 30, 2023 AUD ($)	Jul. 31, 2023 USD ($)	Jul. 12, 2023 shares	Jul. 05, 2023 AUD ($)	Mar. 31, 2023 shares	Sep. 21, 2022 shares	Sep. 20, 2022 shares	May 18, 2022 shares	May 17, 2022 shares
Class of Stock [Line Items]
Common stock shares authorized | shares																	10,000,000,000	10,000,000,000											10,000,000,000	3,000,000,000	3,000,000,000	1,000,000,000
Number of preferred stock authorized shares | shares																													1,500,005		1,500,005
Preferred stock, shares authorized | shares																	1,500,005	1,500,005													3,001,500,005
Total number of authorized shares | shares																													10,001,500,005
Stockholders equity reverse stock split				one-for-one thousand (1:1,000)
Preferred stock, par value | $ / shares																	$ 0.01	$ 0.01
Shares issued | shares																			15,768,400		1,755,240		1,390,008
Stock issued during period, value																	$ 23,057	$ 48,469
Aggregate value																	478,802	6,031
Shares issued price per share | $ / shares																			$ 0.0008		$ 0.0013		$ 0.006
Gross proceeds												$ 24,711					23,057	$ 24,711
Subscription receivable value																	$ 23,758
Common stock per share | $ / shares																	$ 0.001	$ 0.001
Subscription receivable																			$ 11,975		$ 2,260	$ 8,822	$ 8,822
Warrants exercised | shares																	478,802,488	6,031,250
Investor loan, value																	$ 130,800	$ 168,200						$ 71,629
Accrued interest																	8,700	16,632
Conversion fees																	3,832	1,838
Loss on extinguishment debt conversion																	209,233	369,602
Debt conversion fair value																	263,798	352,051
Gains losses on extinguishment of debt																	54,565	25,969
Stock issued during period value services																		138,947
Share based compensation																		2,408
Deemed dividend																	192,960	466,273
Debt discount to be amortized																	$ 294,005	$ 202,952
Restricted stock units, value | $ / shares
Warrants term																				5 years
Warrants exercisable | shares																		13
Issuance of common stock for exercise of warrants | shares					4
Warrants aggregate price																		$ 475,000
Proceeds from warrants exercise																		475,000
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Restricted stock units, shares | shares																0.117
Restricted stock units, value | $ / shares																$ 4,250,000
Series B Warrant [Member]
Class of Stock [Line Items]
Offer from Series B warrants																		$ 475,000
Warrants exercised | shares																		12
Share price | $ / shares																		$ 40,000
Series A Warrants [Member]
Class of Stock [Line Items]
Stock issued during period | shares																	6,272,000	559,999
Warrants exercised | shares																	6,272,000	559,999
Warrants exercised | shares																	0.0314	0.97
Share price | $ / shares																	$ 0.0314	$ 0.97
Warrants exercise price | $ / shares																	200,000	200,000
Alternate cashless warrant exercise price | $ / shares																	$ 0.001	$ 0.001
Percentage of exercise price and market price																	70%
Series A Warrant [Member]
Class of Stock [Line Items]
Warrants exercise price | $ / shares																	$ 200,000
Series B Warrants [Member]
Class of Stock [Line Items]
Shares issued | shares					3
Warrants exercised | shares																		12
Share issued value					$ 100,000
Proceeds from warrants exercise																		$ 475,000
Consultant Services [Member]
Class of Stock [Line Items]
Stock issued during period shares for services | shares																		608,423
Consultant Three [Member] | Consultant Services [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares																		$ 0.135
Stock issued during period value services																		$ 82,137
Share based compensation																		82,137
Stock issued during period shares | shares		608,423
Fair Value [Member]
Class of Stock [Line Items]
Gains losses on extinguishment of debt																		$ 17,551
Convertible Debt [Member]
Class of Stock [Line Items]
Stock issued during period | shares																	445,963,937	5,061,180
Warrants exercised | shares																		807,230								807,230
Average contractual conversion prices | $ / shares																	$ 0.0013	$ 0.17
Investor loan, value																	$ 531,654	$ 935,699
Accrued interest																	28,829	80,586
Conversion fees																	3,832	1,838
Debt instrument fair value																	$ 352,565	$ 556,272
Convertible Debt [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Measurement input																		5.24
Convertible Debt [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Measurement input																	323.40	334.56
Common Stock [Member]
Class of Stock [Line Items]
Stock issued during period, value																	$ 18,914	$ 14
Stock issued during period | shares												14,337					18,913,648	14,337
Shares issued price per share | $ / shares												$ 2
Stock issued during period shares for services | shares						73,301												79,412
Stock issued during period value services																		$ 79
Issuance of common stock for exercise of warrants | shares					4													12
Warrants aggregate price
Issue of warrants | shares																	445,963,937	5,061,180
Common Stock [Member] | Series A Warrants [Member]
Class of Stock [Line Items]
Warrants exercised | shares																		206,000
Common Stock [Member] | Series B Warrants [Member]
Class of Stock [Line Items]
Stock issued during period, value																		$ 40,000
Stock issued during period | shares																		12
Common Stock [Member] | Consultant [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares						$ 0.07	$ 0.07			$ 0.90
Stock issued during period shares for services | shares							73,301			6,111
Stock issued during period value services						$ 51,311				$ 5,500
Share based compensation																		$ 51,311
Series B Warrants [Member]
Class of Stock [Line Items]
Offer from Series B warrants					$ 250
Warrant [Member]
Class of Stock [Line Items]
Common stock per share | $ / shares											$ 10
Warrants exercised | shares											1,000
Warrants aggregate price					$ 150,000
Warrants expiration date											Aug. 16, 2025
Fair value adjustment of warrants											$ 2,408
Stock valuation price per share | $ / shares											$ 2.60						$ 0.119
Warrant exercise price | $ / shares											$ 10						$ 0.01
Share based compensation expenses																		2,408
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Class of Stock [Line Items]
Measurement input											0						0
Warrant [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term											3 years
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Measurement input											3.19						4.59
Warrant [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Measurement input											236						268
Warrant [Member] | Affiliated Entity [Member]
Class of Stock [Line Items]
Common stock per share | $ / shares											$ 10
Gains losses on extinguishment of debt																		$ 17,499
Warrants exercised | shares											2,305						15,000,000
Fair value adjustment of warrants											$ 5,551
Stock valuation price per share | $ / shares											$ 2.60
Warrant exercise price | $ / shares											$ 10
Warrants outstanding payable											$ 23,050
Warrant [Member] | Affiliated Entity [Member] | Measurement Input, Expected Dividend Rate [Member]
Class of Stock [Line Items]
Measurement input											0
Warrant [Member] | Affiliated Entity [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term											3 years						3 years
Warrant [Member] | Affiliated Entity [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Measurement input											3.19
Warrant [Member] | Affiliated Entity [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Measurement input											236
Maximum [Member] | Convertible Debt [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term																	3 months 10 days	8 months 23 days
Maximum [Member] | Convertible Debt [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Measurement input																	5.47
Common Stock Purchase Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Agreement term	24 months
Drawdown description	pursuant to a Drawdown Notice cannot exceed the lesser of (i) 200% of the average daily traded value of the Common Stock during the five (5) business days immediately preceding a Drawdown Notice or (ii) $200,000; provided that in no event may a Drawdown Notice be for less than $5,000, exceed 52,500,000 Shares or cause the Investor’s ownership to exceed 4.99% of the outstanding number of shares of Common Stock immediately prior to the issuance of such Shares. The actual amount of proceeds that the Company will receive in connection with each Drawdown Notice is determined under the Equity Line Agreement by multiplying the number of Shares to be sold by the applicable purchase price per share, which is equal to 85% of the lowest traded price of the Common Stock during the 7 business days immediately following the Clearing Date, less Clearing Costs (as each such term is defined in the Equity Line Agreement)
Common Stock Purchase Agreement [Member] | Maximum [Member] | Investor [Member]
Class of Stock [Line Items]
Sale of stock, value	$ 5,000,000
Common stock per share | $ / shares	$ 0.001
Common Stock Purchase Agreement [Member] | Dutchess [Member]
Class of Stock [Line Items]
Agreement term								36 months					36 months
Percentage of lowest trading price equals purchase price of each shares													92%
Percentage of average daily trading volume									200%				300%
Aggregate value								$ 250,000	$ 250,000				$ 250,000
Beneficial ownership limitation, percentage									9.99%
Common Stock Purchase Agreement [Member] | Dutchess [Member] | Maximum [Member]
Class of Stock [Line Items]
Stock issued during period, value								$ 5,000,000					$ 5,000,000
Underlying Financing Agreements [Member]
Class of Stock [Line Items]
Common stock reserved for future issuances | shares																	6,973,534,490
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Investor loan, value																		$ 65,280
Debt discount to be amortized																	$ 232,700	210,278
Equity purchase agreement description														the Company closed on a transaction related to a Securities Purchase Agreement (the “Securities Purchase Agreement”) entered into on March 30, 2020, whereby an investor purchased from the Company, 7.5 units, each consisting of (i) 1.5 shares of the Company’s common stock, or pre-funded warrants upon Investor’s election due to the 4.99% blocker provision and (ii) 1.5 warrants to purchase one share of Common Stock (“Series A Warrants”, and collectively with the Common Stock the “Units”).
Securities Purchase Agreement [Member] | Prefunded Warrants [Member]
Class of Stock [Line Items]
Warrants exercised | shares														10
Share price | $ / shares														$ 100
Securities Purchase Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Shares issued | shares								75,000	75,000
Investor loan, value								$ 125,000	$ 125,000																$ 142,909
Accrued interest																		$ 22,749							$ 70
Debt discount to be amortized								$ 37,500	$ 37,500
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member]
Class of Stock [Line Items]
Fair value adjustment of warrants																	$ 141,084
Letter Agreement [Member]
Class of Stock [Line Items]
Investor loan, value			$ 153,256																								$ 230,000
Share price | $ / shares			$ 0.01
Fair value adjustment of warrants			$ 141,084
Maturity term			3 years
Issue of warrants | shares			15,000,000
Letter Agreement [Member] | Warrant [Member]
Class of Stock [Line Items]
Stock valuation price per share | $ / shares			$ 0.119
Warrant exercise price | $ / shares			$ 0.01
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Class of Stock [Line Items]
Measurement input			0																								0
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term			3 years
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Measurement input			4.59																								4.59
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Measurement input			268																								268
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares																	500,000
Preferred stock shares outstanding | shares																												0
Shares issued | shares																	0	0
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares																	5	5
Preferred stock, par value | $ / shares																	$ 0.01	$ 0.01
Preferred stock shares outstanding | shares																	1	1
Preferred stock shares issued | shares																	1	1
Shares issued | shares																	0	0
Series B Warrants [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Warrants exercised | shares														64	4
Share price | $ / shares															$ 40,000
Warrants term															3 years
Series B Warrants [Member] | Securities Purchase Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Warrants exercised | shares															64
Warrants exercisable | shares															38
Trading days | Integer															10
Series B Warrants [Member] | Securities Purchase Agreement [Member] | Holder [Member]
Class of Stock [Line Items]
Stock issued during period | shares															4
Series C Warrants [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Warrants exercised | shares														64
Series C Warrants [Member] | Securities Purchase Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Warrants exercised | shares															64
Share price | $ / shares															$ 200,000
Warrants term															3 years
Series A Warrants [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Warrants exercised | shares															11
Series A Warrants [Member] | Securities Purchase Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Share price | $ / shares															$ 200,000
Warrants term															3 years
Warrant description															the Series A Warrants contain a provision for a cashless conversion at the Holder’s option should the trading price of the Common Stock fall below $200,000, per share calculated based on the difference between the exercise price of the Series A Warrant and 70% of the Market Price, as defined therein (the” Alternate Cashless Exercise”). The Alternate Cashless Exercise price is $0.001. See above “Shares issued for exercise of warrants” for discussion of deemed dividend related to alternate cashless exercise

SCHEDULE OF RIGHT OF USE ASSET

SCHEDULE OF RIGHT OF USE ASSET (Details) - Related Party [Member] - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Defined Benefit Plan Disclosure [Line Items]
Office lease	$ 66,201	$ 66,201
Less: accumulated amortization	(48,402)	(27,213)
Right-of-use asset, net	$ 17,799	$ 38,988

SCHEDULE OF OPERATING LEASE LIA

SCHEDULE OF OPERATING LEASE LIABILITY (Details) - Related Party [Member] - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Defined Benefit Plan Disclosure [Line Items]
Office lease	$ 66,201	$ 66,201
Reduction of lease liability	(46,839)	(25,418)
Less: office lease, current portion	(19,362)	(21,505)
Long term portion of lease liability		$ 19,278

SCHEDULE OF FUTURE MINIMUM LEAS

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)	Jun. 30, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Fiscal Year 2025	$ 20,079
Imputed interest	(717)
Total operating lease liability	$ 19,362

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)

1 Months Ended

12 Months Ended

May 04, 2024 USD ($)

Nov. 16, 2022 shares

Nov. 16, 2022 shares

Oct. 25, 2022 shares

Jul. 27, 2022 USD ($)

Jul. 27, 2022 EUR (€)

Jul. 01, 2022 USD ($)

May 04, 2022 USD ($)

May 04, 2022 AUD ($)

Oct. 01, 2020 USD ($)

Oct. 01, 2020 EUR (€)

Sep. 13, 2018 USD ($)

Sep. 13, 2018 EUR (€)

Jul. 31, 2023 USD ($)

Jul. 31, 2023 EUR (€)

Mar. 31, 2023 USD ($)

Mar. 31, 2023 EUR (€)

Dec. 31, 2022 USD ($)

Dec. 31, 2022 EUR (€)

Sep. 30, 2022 USD ($)

Sep. 30, 2022 EUR (€)

Aug. 31, 2022 USD ($)

Aug. 31, 2022 EUR (€)

Dec. 31, 2021 USD ($)

Dec. 31, 2021 EUR (€)

Mar. 31, 2021 USD ($)

Mar. 31, 2021 EUR (€)

Nov. 30, 2020 EUR (€)

Jun. 30, 2012

Jun. 30, 2024 USD ($) shares

Jun. 30, 2023 USD ($) shares

Jul. 05, 2023

Total litigation penalty amount

$ 30,000

Royalties percentage

2%

2%

Unreimbursed lab fees

47,531

$ 18,056

Royalty fees

$ 0

$ 0

Accrued expense | shares

478,802,488

6,031,250

Cash fee percentage

10%

Warrants term

5 years

Deferred offering cost

$ 27,117

Payments for rent

$ 34,150

$ 28,841

Incremental borrowing rate

8%

8%

Weighted average remaining lease term

9 months 3 days

Accounting Standards Update 2016-02 [Member]

Operating lease right of use asset

$ 66,201

Operating lease liabilities

$ 66,201

Maximum [Member]

Cash fee percentage

8%

Equity and Equity Linked Placements [Member]

Cash fee percentage

8%

Debt Placements [Member]

Cash fee percentage

6%

Consultant [Member]

Sale of stock percent

5%

Expenses advance

$ 50,000

Deferred offering cost

$ 25,000

Common Stock [Member]

Stock issued during period shares for services | shares

73,301

79,412

Sale of stock percent

3%

Common Stock [Member] | Consultant [Member]

Stock issued during period shares for services | shares

73,301

6,111

University of Jaen [Member]

Payment for services

$ 30,268

€ 25,837

Royalty Agreement Terms [Member]

Operating leases income statement revenue percentage

2%

License Agreement Terms [Member]

Operating leases income statement revenue percentage

5%

1-Year Collaboration Agreement [Member]

Payment for services

$ 59,508

€ 52,000

2-Year Collaboration Agreement [Member]

Payment for services

$ 35,145

€ 30,000

$ 45,775

€ 40,000

Royalty percentage

2%

2%

Research Agreement [Member] | University of Jaen [Member]

Payment for services

$ 53,806

€ 53,200

Royalty percentage

1%

1%

Consulting Agreement [Member]

Monthly Fee

$ 50,000

Stock fee percentage

9.90%

9.90%

Accrued expense | shares

608,423

Other liabilities

$ 0

Underwriting Agreement [Member] | EF Hutton LLC [Member]

Sale of underwriting agreements

$ 15,000,000

Merger Acquisition Agreement [Member] | Consultant [Member]

Expenses advance

25,000

Initial Payable [Member] | Consultant [Member]

Expenses advance

$ 25,000

New Three-Year Operating Lease Agreement [Member]

Lessee operating lease term

3 years

Payments for rent

$ 2,176

$ 3,000

From 2012 through the 2014 [Member]

Total litigation penalty amount

$ 10,000

Installment 1 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services | €

€ 5,000

Installment 1 [Member] | Research Agreement [Member]

Payment for services

$ 18,407

€ 18,200

Installment 2 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 5,858

€ 5,000

Installment 2 [Member] | Research Agreement [Member]

Payment for services

$ 8,091

€ 8,000

Installment 3 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 11,715

€ 10,000

Installment 3 [Member] | Research Agreement [Member]

Payment for services

$ 7,080

€ 7,000

Installment 4 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 11,715

€ 10,000

Installment 4 [Member] | Research Agreement [Member]

Payment for services

$ 10,114

€ 10,000

Installment 5 [Member] | Research Agreement [Member]

Payment for services

$ 10,114

€ 10,000

RELATED PARTY TRANSACTIONS AN_2

RELATED PARTY TRANSACTIONS AND BALANCES (Details Narrative)																					1 Months Ended			12 Months Ended
	Jul. 05, 2023 USD ($) $ / shares shares	Oct. 26, 2022 USD ($)	Oct. 26, 2022 AUD ($)	Aug. 01, 2022 USD ($)	Aug. 01, 2022 AUD ($)	May 04, 2022 USD ($)	May 04, 2022 AUD ($)	Aug. 12, 2021 USD ($) shares	May 14, 2019 USD ($) $ / shares shares	May 14, 2019 AUD ($) shares	Mar. 16, 2018 USD ($)	Mar. 16, 2018 AUD ($)	Feb. 01, 2018 USD ($)	Feb. 01, 2018 AUD ($)	May 05, 2016 USD ($)	May 05, 2016 AUD ($)	Feb. 25, 2016 USD ($)	Feb. 25, 2016 AUD ($)	Feb. 25, 2015 USD ($)	Feb. 25, 2015 AUD ($)	Jan. 31, 2024 USD ($)	Jan. 31, 2024 AUD ($)	May 31, 2019 shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 AUD ($) shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2023 AUD ($) shares	Jun. 30, 2022 USD ($)	Jun. 30, 2022 AUD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 AUD ($)	Jun. 30, 2024 AUD ($)	May 04, 2024	Nov. 30, 2023 AUD ($)	Jul. 05, 2023 AUD ($)	Jun. 30, 2023 AUD ($)	May 05, 2016 AUD ($)
Related Party Transaction [Line Items]
Payments for rent | $																								$ 34,150		$ 28,841
Investor loan, value																								130,800		168,200								$ 71,629
Debt instrument interest rate stated percentage	10%																																		10%
Bonus payable																					$ 102,195	$ 150,000		$ 16,070	$ 25,000	$ 48,905	$ 73,387	$ 99,691	$ 144,166
Exercise price | $ / shares
Granted exercise price | $ / shares
Accrued salaries																								$ 97,044		$ 64,627						$ 148,000				$ 96,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Payments form related party | $																															$ 221,890
Bonus payable																														$ 166,418	$ 422,610
Remaining bonus amount																								$ 145,599	$ 217,540	$ 71,929	$ 107,937	125,386	181,324
Restricted stock shares of common stock																							0.078
Maximum [Member]
Related Party Transaction [Line Items]
Debt instrument interest rate stated percentage																																	8%
Letter Agreement [Member]
Related Party Transaction [Line Items]
Investor loan, value	$ 153,256																																		$ 230,000
Term of agreement	3 years
Debt instrument maturity date	Jul. 05, 2026
Debt instrument interest rate stated percentage	10%																																		10%
Issue of warrants	15,000,000
Share price | $ / shares	$ 0.01
Nathanielsz Employment Agreement [Member]
Related Party Transaction [Line Items]
Expired date																			Feb. 25, 2019	Feb. 25, 2019
Base salary per month | $																				$ 25,000
Annual salary		$ 414,900	$ 600,000																$ 205,680	$ 300,000
Percentage of pension of monthly salary																										9.50%	9.50%
Percentage of bonus of annual base salary																								200%	200%
Nathanielsz Employment Agreement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Annual salary				$ 414,900	$ 600,000						$ 274,240	$ 400,000
Percentage of bonus of annual base salary																			200%	200%				100%	100%
Nathanielsz Employment Agreement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Annual salary				309,313	400,000						$ 205,680	$ 300,000
Mrs. Nathanielsz [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Bonus payable | $																														$ 316,957
Services Agreement [Member]
Related Party Transaction [Line Items]
Number of restricted stock unit vested, shares																								0.02	0.02
Restricted stock unit issuable																										0.02	0.02
Services Agreement [Member] | Initial Kenyon RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock									0.02	0.02
Services Agreement [Member] | Additional Kenyon RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock									0.02	0.02
Employment Agreement [Member]
Related Party Transaction [Line Items]
Number of restricted stock unit vested, shares																								0.04	0.04
Employment Agreement [Member] | Initial Nathanielsz RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock									0.04	0.04																0.04	0.04
Employment Agreement [Member] | Additional Nathanielsz RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock unit issuable																										0.04	0.04
Accounting Standards Update 2016-02 [Member]
Related Party Transaction [Line Items]
Operating lease, description															Such lease expired in May 2021 and was renewed for another one-year term from May 2021 to May 2022.	Such lease expired in May 2021 and was renewed for another one-year term from May 2021 to May 2022.
North Horizon Pty Ltd [Member]
Related Party Transaction [Line Items]
Lessee, operating lease, term of contract															5 years																						5 years
Operating leases rent expense, minimum rentals															$ 28,325	$ 39,600
Goods and service tax															2,575	$ 3,600
Payments for rent																								$ 129,930	$ 194,129	$ 105,377	$ 158,129
North Horizon Pty Ltd [Member] | Three Year Operating Lease Agreement [Member]
Related Party Transaction [Line Items]
Payments for rent						$ 2,176	$ 3,000
Former Director [Member]
Related Party Transaction [Line Items]
Loans from related party | $																								29,759		29,630
Due to related parties | $																								49,528		49,314
Nathanielsz [Member] | North Horizon Pty Ltd [Member]
Related Party Transaction [Line Items]
Operating leases, future minimum payments due															$ 141,629																						$ 198,000
Mrs. Nathanielsz [Member]
Related Party Transaction [Line Items]
Annual salary													$ 80,904	$ 120,000
Payments form related party																								$ 17,714		$ 3,344		$ 5,577	$ 7,689
James Nathanielsz [Member]
Related Party Transaction [Line Items]
Payments form related party																	$ 3,205	$ 4,481
Mr. Nathanielsz [Member] | Board of Directors [Member]
Related Party Transaction [Line Items]
Officers compensation				$ 96,810	$ 140,000			$ 177,840
Debt conversion, converted instrument, shares issued								5,928,000
Mr. Nathanielsz [Member] | Employment Agreement [Member]
Related Party Transaction [Line Items]
Annual salary									$ 309,313	$ 400,000
Option purchase shares									0.04	0.04
Exercise price | $ / shares									$ 4,675,000
Market price									110%	110%
Granted exercise price | $ / shares									$ 4,250,000
Option term									10 years	10 years
Dr. Kenyon [Member] | Services Agreement [Member]
Related Party Transaction [Line Items]
Annual salary									$ 41,580	$ 54,000
Agreement term									3 years	3 years
Option purchase shares									0.02	0.02
Exercise price | $ / shares									$ 4,250,000
Market price									100%	100%
Option term									10 years	10 years

CONCENTRATIONS AND RISKS (Detai

CONCENTRATIONS AND RISKS (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Concentration Risk [Line Items]
Discounts and debt issuance cost	$ 103,900	$ 79,111
Proceeds from convertible debt	$ 567,050	$ 590,250
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender One [Member]
Concentration Risk [Line Items]
Concentration risk percentage	28%	17%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Two [Member]
Concentration Risk [Line Items]
Concentration risk percentage	14%	32%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Three [Member]
Concentration Risk [Line Items]
Concentration risk percentage	12%	25%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Four [Member]
Concentration Risk [Line Items]
Concentration risk percentage	11%	8%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Five [Member]
Concentration Risk [Line Items]
Concentration risk percentage	21%	18%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Receivable [Member]
Concentration Risk [Line Items]
Concentration risk percentage	100%	100%
Lender One [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 295,000	$ 101,250
Lender Two [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	150,000	189,000
Lender Three [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	127,500	150,000
Lender Four [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	120,000	50,000
Lender Five [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 224,885	$ 100,000

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Measurement Input, Price Volatility [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	323.40	334.56
Measurement Input, Price Volatility [Member] | New Derivative Instruments [Member] | Minimum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	323.40
Measurement Input, Price Volatility [Member] | New Derivative Instruments [Member] | Maximum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	333.45
Measurement Input, Expected Term [Member] | Minimum [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, term	3 days	3 days
Measurement Input, Expected Term [Member] | Maximum [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, term	3 months 10 days	8 months 23 days
Measurement Input, Expected Term [Member] | New Derivative Instruments [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, term	6 months
Measurement Input, Risk Free Interest Rate [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages		5.24
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	5.45
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	5.47
Measurement Input, Risk Free Interest Rate [Member] | New Derivative Instruments [Member] | Minimum [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	5.42
Measurement Input, Risk Free Interest Rate [Member] | New Derivative Instruments [Member] | Maximum [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	5.55

SCHEDULE OF FAIR VALUE, ASSETS

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Platform Operator, Crypto Asset [Line Items]
Embedded conversion option liabilities	$ 133,886	$ 423,209
Total	133,886	423,209
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto Asset [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto Asset [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto Asset [Line Items]
Embedded conversion option liabilities	133,886	423,209
Total	$ 133,886	$ 423,209

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Beginning balance	$ 423,209
Gain on debt extinguishment	(54,565)	$ (25,969)
Change in fair value included in statements of operations	(316,537)	530,330
Ending balance	133,886	423,209
Derivative [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Beginning balance	423,209	151,262
Initial fair value of embedded conversion option derivative liability recorded as debt discount	150,000	93,668
Gain on debt extinguishment	(263,798)	(352,051)
Change in fair value included in statements of operations	(316,537)	530,330
Initial fair value of embedded conversion option derivative liability recorded as derivative expense	141,012
Ending balance	$ 133,886	$ 423,209

DERIVATIVE FINANCIAL INSTRUME_3

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Share price	$ 0.0013
Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Convertible debt	$ 110,500	$ 75,300

SCHEDULE OF LOSS PER SHARE BASI

SCHEDULE OF LOSS PER SHARE BASIS OF REVERSE STOCK SPLIT (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Net losses available to common stockholders	$ (2,013,488)	$ (3,126,839)
Basic weighted average shares outstanding	85,045,339	1,738,802
Diluted weighted average shares outstanding	85,045,339	1,738,802
Basic net loss per share	$ (0.02)	$ (1.80)
Diluted net loss per share	$ (0.02)	$ (1.80)
Pre-Reverse Stock Split [Member]
Net losses available to common stockholders	$ 2,013,488	$ 3,126,839
Basic weighted average shares outstanding	85,045,339	1,738,802
Diluted weighted average shares outstanding	85,045,339	1,738,802
Basic net loss per share	$ 0.02	$ 1.80
Diluted net loss per share	$ 0.02	$ 1.80
Post-Reverse Stock Split [Member]
Net losses available to common stockholders	$ 2,013,488	$ 3,126,839
Basic weighted average shares outstanding	850	17
Diluted weighted average shares outstanding	850	17
Basic net loss per share	$ 2,368.81	$ 183,931.71
Diluted net loss per share	$ 2,368.81	$ 183,931.71
Reverse Stock Split 1:10,000 [Member]
Net losses available to common stockholders	$ 2,013,488	$ 3,126,839
Basic weighted average shares outstanding	8,505	174
Diluted weighted average shares outstanding	8,505	174
Basic net loss per share	$ 236.74	$ 17,970
Diluted net loss per share	$ 236.74	$ 17,970
Reverse Stock Split 1:50,000 [Member]
Net losses available to common stockholders	$ 2,013,488	$ 3,126,839
Basic weighted average shares outstanding	1,701	35
Diluted weighted average shares outstanding	1,701	35
Basic net loss per share	$ 1,183.71	$ 89,338.26
Diluted net loss per share	$ 1,183.71	$ 89,338.26
Reverse Stock Split 1:100,000 [Member]
Net losses available to common stockholders	$ 2,013,488	$ 3,126,839
Basic weighted average shares outstanding	850	17
Diluted weighted average shares outstanding	850	17
Basic net loss per share	$ 2,368.81	$ 183,931.71
Diluted net loss per share	$ 2,368.81	$ 183,931.71

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)

3 Months Ended

12 Months Ended

Aug. 12, 2024 USD ($) $ / shares shares

Aug. 07, 2024

Aug. 02, 2024 USD ($)

Aug. 01, 2024 USD ($)

Apr. 12, 2024 USD ($)

Oct. 12, 2023 USD ($)

Aug. 23, 2023 USD ($)

Jul. 05, 2023 USD ($)

May 01, 2023

Sep. 21, 2022 USD ($)

Aug. 12, 2022 USD ($)

Jul. 01, 2022 USD ($)

Oct. 03, 2019

Sep. 19, 2024 USD ($) $ / shares shares

Jun. 30, 2024 USD ($) $ / shares

Jun. 30, 2023 USD ($) $ / shares

Aug. 26, 2024 USD ($)

Aug. 26, 2024 AUD ($)

Aug. 01, 2024 AUD ($)

Jun. 30, 2024 AUD ($)

May 04, 2024

Nov. 30, 2023 AUD ($)

Jul. 05, 2023 AUD ($)

Subsequent Event [Line Items]

Principal amount

$ 130,800

$ 168,200

$ 71,629

Debt instrument interest rate stated percentage

10%

10%

Debt instrument strike price

4.99%

Original issue discount

$ 38,854

38,994

Debt instrument debt default interest rate

24%

Penalty amount

30,000

Accrued interest

8,700

16,632

Conversion fees

3,832

1,838

Debt instrument unamortized premium

$ 124,629

$ 91,171

Common stock, par value | $ / shares

$ 0.001

$ 0.001

Stock Issued During Period, Value, New Issues

$ 23,057

$ 48,469

Reverse stock split

one-for-one thousand (1:1,000)

Maximum [Member]

Subsequent Event [Line Items]

Debt instrument interest rate stated percentage

8%

GS Capital Partners, LLC [Member]

Subsequent Event [Line Items]

Accrued interest

8,700

2,945

Loan Agreement [Member]

Subsequent Event [Line Items]

Principal amount

$ 79,811

$ 120,000

Debt instrument interest rate stated percentage

12%

12%

Accrued interest

$ 665

Letter Agreement [Member]

Subsequent Event [Line Items]

Principal amount

$ 153,256

$ 230,000

Maturity date

Jul. 05, 2026

Debt instrument interest rate stated percentage

10%

10%

Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Principal amount

65,280

Maturity date

Oct. 03, 2020

Debt instrument unamortized premium

279,711

232,674

Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]

Subsequent Event [Line Items]

Principal amount

$ 27,500

$ 61,000

$ 77,500

$ 71,500

$ 93,000

$ 83,000

Maturity date

Oct. 12, 2024

Apr. 12, 2024

Feb. 23, 2024

Mar. 21, 2023

Apr. 12, 2023

Debt instrument interest rate stated percentage

8%

8%

8%

8%

8%

Debt instrument strike price

65%

65%

Original issue discount

$ 2,500

$ 3,500

$ 5,000

$ 4,000

$ 5,000

Conversion price, description

The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0017 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.001 per share in the event that the market price of the Common Stock trades below $0.0014 per share for five consecutive trading days

The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.015 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.01 per share in the event that the market price of the Common Stock trades below $0.0075 per share for ten consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default

The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.04 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.02 per share in the event that the market price of the Common Stock trades below $0.03 per share for five consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default

Such note was exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2 (the “September Fixed Price”). However, in the event the common stock trades below $1.40 per share for more than five consecutive trading days, then the September Fixed Price becomes $0.90 per share

The GS Capital Note was exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital by surrendering the same. GS Capital was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2.80 per share (the “Fixed Price”). However, in the event the common stock trades below $2 per share for more than five consecutive trading days, then the Fixed Price becomes $1.30 per share

Debt instrument debt default interest rate

24%

Debt instrument increase principal percentage

20%

Accrued interest

$ 8,364

$ 4,263

Conversion fees

$ 3,832

Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Minimum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

110%

Penalty amount

$ 250

Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Maximum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

125%

Penalty amount

$ 500

Consulting Agreement [Member]

Subsequent Event [Line Items]

Monthly Fee

$ 50,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Principal amount

$ 44,925

New issuance, shares | shares

209,219,529

Debt instrument contractual conversion price | $ / shares

$ 0.0003

Accrued interest

$ 7,053

Conversion fees

2,548

Debt instrument unamortized premium

$ 9,337

Reverse stock split

reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio somewhere between one post-split share per ten thousand pre-split shares (1:10,000) and one post-split share per one hundred thousand pre-split shares (1:100,000) (the “Reverse Stock Split”)

Subsequent Event [Member] | Loan Agreement [Member]

Subsequent Event [Line Items]

Principal amount

$ 85,000

$ 150,000

Maturity date

Nov. 01, 2024

Debt instrument loan bears interest rate

12%

Debt instrument interest rate stated percentage

18%

18%

Debt instrument strike price

35%

Subsequent Event [Member] | Letter Agreement [Member]

Subsequent Event [Line Items]

Principal amount

$ 97,649

$ 57,638

Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]

Subsequent Event [Line Items]

Principal amount

$ 33,000

Maturity date

Feb. 02, 2025

Debt instrument interest rate stated percentage

8%

Original issue discount

$ 3,000

Conversion price, description

The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0017 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.001 per share in the event that the market price of the Common Stock trades below $0.0014 per share for five consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. Pursuant to the Note, in the event that such conversion price is below the par value of the Common Stock, the Company has agreed to take all steps to reduce such par value or conduct a reverse split of its Common Stock, as applicable. Notwithstanding the foregoing, such conversion price and lookback periods are subject to adjustment in favor of the investor in the event the Company issues securities to another party with more favorable conversion terms, and such conversions are subject to a 4.99% beneficial ownership limitation (which may be increased to 9.9% upon 60 days’ prior written notice from the holder of the Note). The GS Capital note shall be bifurcated from the embedded conversion option which was recorded as derivative liabilities at fair value.

Debt instrument debt default interest rate

24%

Debt instrument increase principal percentage

20%

Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Minimum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

110%

Penalty amount

$ 250

Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Maximum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

125%

Penalty amount

$ 500

Subsequent Event [Member] | Consulting Agreement [Member]

Subsequent Event [Line Items]

New issuance, shares | shares

15,000,000

Monthly Fee

$ 7,500

Common stock, par value | $ / shares

$ 0.001

Stock Issued During Period, Value, New Issues

$ 15,000